<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/401315</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;401315</article-id><article-id pub-id-type="other" hwp:sub-type="slug">401315</article-id><article-id pub-id-type="other" hwp:sub-type="tag">401315</article-id><article-version>1.1</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Microbiology" hwp:journal="biorxiv"><subject>Microbiology</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures</article-title></title-group><author-notes hwp:id="author-notes-1"><corresp id="cor1" hwp:id="corresp-1" hwp:rev-id="xref-corresp-1-1 xref-corresp-1-2"><label>*</label>Corresponding authors: <email hwp:id="email-1">olivier.terrier@univ-lyon1.fr</email> (OT), <email hwp:id="email-2">manuel.rosa-calatrava@univ-lyon1.fr</email> (MRC)</corresp><fn id="n1" hwp:id="fn-1" hwp:rev-id="xref-fn-1-1 xref-fn-1-2"><label>¶</label><p hwp:id="p-1">These authors contributed equally to this work</p></fn></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" hwp:id="contrib-1"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0918-6804</contrib-id><name name-style="western" hwp:sortable="Pizzorno Andrés"><surname>Pizzorno</surname><given-names>Andrés</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-1" hwp:rel-id="aff-2">2</xref><xref ref-type="fn" rid="n1" hwp:id="xref-fn-1-1" hwp:rel-id="fn-1">¶</xref><object-id pub-id-type="other" hwp:sub-type="orcid" xlink:href="http://orcid.org/0000-0002-0918-6804"/></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-2"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9393-7684</contrib-id><name name-style="western" hwp:sortable="Terrier Olivier"><surname>Terrier</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-2" hwp:rel-id="aff-1">1</xref><xref ref-type="fn" rid="n1" hwp:id="xref-fn-1-2" hwp:rel-id="fn-1">¶</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-1" hwp:rel-id="corresp-1">*</xref><object-id pub-id-type="other" hwp:sub-type="orcid" xlink:href="http://orcid.org/0000-0001-9393-7684"/></contrib><contrib contrib-type="author" hwp:id="contrib-3"><name name-style="western" hwp:sortable="de Lamballerie Claire Nicolas"><surname>de Lamballerie</surname><given-names>Claire Nicolas</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-3" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-1" hwp:rel-id="aff-3">3</xref></contrib><contrib contrib-type="author" hwp:id="contrib-4"><name name-style="western" hwp:sortable="Julien Thomas"><surname>Julien</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-4" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-1" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" hwp:id="contrib-5"><name name-style="western" hwp:sortable="Padey Blandine"><surname>Padey</surname><given-names>Blandine</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-5" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-2" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" hwp:id="contrib-6"><name name-style="western" hwp:sortable="Traversier Aurélien"><surname>Traversier</surname><given-names>Aurélien</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-6" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-7"><name name-style="western" hwp:sortable="Roche Magali"><surname>Roche</surname><given-names>Magali</given-names></name><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-2" hwp:rel-id="aff-3">3</xref></contrib><contrib contrib-type="author" hwp:id="contrib-8"><name name-style="western" hwp:sortable="Hamelin Marie-Eve"><surname>Hamelin</surname><given-names>Marie-Eve</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-2" hwp:rel-id="aff-2">2</xref></contrib><contrib contrib-type="author" hwp:id="contrib-9"><name name-style="western" hwp:sortable="Rhéaume Chantal"><surname>Rhéaume</surname><given-names>Chantal</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-3" hwp:rel-id="aff-2">2</xref></contrib><contrib contrib-type="author" hwp:id="contrib-10"><name name-style="western" hwp:sortable="Croze Séverine"><surname>Croze</surname><given-names>Séverine</given-names></name><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-1" hwp:rel-id="aff-5">5</xref></contrib><contrib contrib-type="author" hwp:id="contrib-11"><name name-style="western" hwp:sortable="Escuret Vanessa"><surname>Escuret</surname><given-names>Vanessa</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-7" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a6" hwp:id="xref-aff-6-1" hwp:rel-id="aff-6">6</xref></contrib><contrib contrib-type="author" hwp:id="contrib-12"><name name-style="western" hwp:sortable="Poissy Julien"><surname>Poissy</surname><given-names>Julien</given-names></name><xref ref-type="aff" rid="a7" hwp:id="xref-aff-7-1" hwp:rel-id="aff-7">7</xref></contrib><contrib contrib-type="author" hwp:id="contrib-13"><name name-style="western" hwp:sortable="Lina Bruno"><surname>Lina</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-8" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a6" hwp:id="xref-aff-6-2" hwp:rel-id="aff-6">6</xref></contrib><contrib contrib-type="author" hwp:id="contrib-14"><name name-style="western" hwp:sortable="Legras-Lachuer Catherine"><surname>Legras-Lachuer</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-3" hwp:rel-id="aff-3">3</xref><xref ref-type="aff" rid="a8" hwp:id="xref-aff-8-1" hwp:rel-id="aff-8">8</xref></contrib><contrib contrib-type="author" hwp:id="contrib-15"><name name-style="western" hwp:sortable="Textoris Julien"><surname>Textoris</surname><given-names>Julien</given-names></name><xref ref-type="aff" rid="a9" hwp:id="xref-aff-9-1" hwp:rel-id="aff-9">9</xref><xref ref-type="aff" rid="a10" hwp:id="xref-aff-10-1" hwp:rel-id="aff-10">10</xref></contrib><contrib contrib-type="author" hwp:id="contrib-16"><name name-style="western" hwp:sortable="Boivin Guy"><surname>Boivin</surname><given-names>Guy</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-4" hwp:rel-id="aff-2">2</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-17"><name name-style="western" hwp:sortable="Rosa-Calatrava Manuel"><surname>Rosa-Calatrava</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-9" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-4" hwp:rel-id="aff-3">3</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-2" hwp:rel-id="corresp-1">*</xref></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1 xref-aff-1-2 xref-aff-1-3 xref-aff-1-4 xref-aff-1-5 xref-aff-1-6 xref-aff-1-7 xref-aff-1-8 xref-aff-1-9"><label>1</label><institution hwp:id="institution-1">Virologie et Pathologie Humaine - VirPath team, Centre International de Recherche en Infectiologie (CIRI)</institution>, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon 69008, <country>France</country></aff><aff id="a2" hwp:id="aff-2" hwp:rev-id="xref-aff-2-1 xref-aff-2-2 xref-aff-2-3 xref-aff-2-4"><label>2</label><institution hwp:id="institution-2">Research Center in Infectious Diseases of the CHU de Quebec and Laval University</institution>, Quebec City, QC G1V 4G2, <country>Canada</country></aff><aff id="a3" hwp:id="aff-3" hwp:rev-id="xref-aff-3-1 xref-aff-3-2 xref-aff-3-3 xref-aff-3-4"><label>3</label><institution hwp:id="institution-3">Viroscan3D SAS</institution>, Lyon 69008, <country>France</country></aff><aff id="a4" hwp:id="aff-4" hwp:rev-id="xref-aff-4-1 xref-aff-4-2"><label>4</label><institution hwp:id="institution-4">VirNext</institution>, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon 69008, <country>France</country></aff><aff id="a5" hwp:id="aff-5" hwp:rev-id="xref-aff-5-1"><label>5</label><institution hwp:id="institution-5">ProfileXpert</institution>, SFR-Est, CNRS UMR-S3453, INSERM US7, Université Claude Bernard Lyon 1, Université de Lyon, Lyon 69008, <country>France</country></aff><aff id="a6" hwp:id="aff-6" hwp:rev-id="xref-aff-6-1 xref-aff-6-2"><label>6</label><institution hwp:id="institution-6">Laboratoire de Virologie, Centre National de Référence des virus Influenza Sud, Institut desAgents Infectieux, Groupement Hospitalier Nord</institution>, Hospices Civils de Lyon, Lyon F-21 <country>France</country></aff><aff id="a7" hwp:id="aff-7" hwp:rev-id="xref-aff-7-1"><label>7</label><institution hwp:id="institution-7">Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional 22 et Universitaire de Lille</institution>, Université de Lille 2, Lille 59000, <country>France</country></aff><aff id="a8" hwp:id="aff-8" hwp:rev-id="xref-aff-8-1"><label>8</label><institution hwp:id="institution-8">Ecologie Microbienne</institution>, UMR CNRS 5557, USC INRA 1364, Université Claude Bernard Lyon 1, Université de Lyon, Villeurbanne 69100, <country>France</country></aff><aff id="a9" hwp:id="aff-9" hwp:rev-id="xref-aff-9-1"><label>9</label><institution hwp:id="institution-9">Service d’Anesthésie et de Réanimation, Hôpital Edouard Herriot</institution>, Hospices Civils de Lyon, Lyon 69003, <country>France</country></aff><aff id="a10" hwp:id="aff-10" hwp:rev-id="xref-aff-10-1"><label>10</label><institution hwp:id="institution-10">Pathophysiology of Injury-Induced Immunosuppression (PI3)</institution>, EA 7426 Hospices Civils de Lyon,bioMérieux, Université Claude Bernard Lyon 1, Hôpital Edouard Herriot, Lyon 69003, <country>France</country></aff></contrib-group><pub-date pub-type="epub-original" hwp:start="2018"><year>2018</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2018-08-27T16:33:17-07:00">
    <day>27</day><month>8</month><year>2018</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2018-08-27T16:33:17-07:00">
    <day>27</day><month>8</month><year>2018</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2018-08-27T16:40:16-07:00">
    <day>27</day><month>8</month><year>2018</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2018-08-27T16:40:16-07:00">
    <day>27</day><month>8</month><year>2018</year>
  </pub-date><elocation-id>401315</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2018-08-27"><day>27</day><month>8</month><year>2018</year></date>
<date date-type="rev-recd" hwp:start="2018-08-27"><day>27</day><month>8</month><year>2018</year></date>
<date date-type="accepted" hwp:start="2018-08-27"><day>27</day><month>8</month><year>2018</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2018</copyright-year><license hwp:id="license-1"><p hwp:id="p-2">The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.</p></license></permissions><self-uri xlink:href="401315.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2019/pdf/401315v1.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="401315.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2019/abstracts/401315v1/401315v1.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2019/fulltext/401315v1/401315v1.htslp"/><abstract hwp:id="abstract-1"><title hwp:id="title-1">Abstract</title><sec hwp:id="sec-1"><title hwp:id="title-2">Background:</title><p hwp:id="p-3">Influenza virus infections remain a major and recurrent public health burden. The intrinsic ever-evolving nature of this virus, the suboptimal efficacy of current influenza inactivated vaccines, as well as the emergence of resistance against a limited antiviral arsenal, highlight the critical need for novel therapeutic approaches. In this context, the aim of this study was to develop and validate an innovative strategy for drug repurposing as host-targeted inhibitors of influenza viruses and the rapid evaluation of the most promising candidates in Phase II clinical trials.</p></sec><sec hwp:id="sec-2"><title hwp:id="title-3">Methods:</title><p hwp:id="p-4">We exploited <italic toggle="yes">in vivo</italic> global transcriptomic signatures of infection directly obtained from a patient cohort to determine a shortlist of already marketed drugs with newly identified, host-targeted inhibitory properties against influenza virus. The antiviral potential of selected repurposing candidates was further evaluated <italic toggle="yes">in vitro, in vivo</italic> and <italic toggle="yes">ex vivo</italic>.</p></sec><sec hwp:id="sec-3"><title hwp:id="title-4">Results:</title><p hwp:id="p-5">Our strategy allowed the selection of a shortlist of 35 high potential candidates out of a rationalized computational screening of 1,309 FDA-approved bioactive molecules, 31 of which were validated for their significant <italic toggle="yes">in vitro</italic> antiviral activity. Our <italic toggle="yes">in vivo</italic> and <italic toggle="yes">ex vivo</italic> results highlight diltiazem, a calcium channel blocker currently used in the treatment of hypertension, as a promising option for the treatment of influenza infections. Additionally, transcriptomic signature analysis further revealed the so far undescribed capacity of diltiazem to modulate the expression of specific genes related to the host antiviral response and cholesterol metabolism. Finally, combination treatment with diltiazem and virus-targeted oseltamivir neuraminidase inhibitor further increased antiviral efficacy, prompting rapid authorization for the initiation of a Phase II clinical trial.</p></sec><sec hwp:id="sec-4"><title hwp:id="title-5">Conclusions:</title><p hwp:id="p-6">This original, host-targeted, drug repurposing strategy constitutes an effective and highly reactive process for the rapid identification of novel anti-infectious drugs, with potential major implications for the management of antimicrobial resistance and the rapid response to future epidemic or pandemic (re)emerging diseases for which we are still disarmed.</p></sec></abstract><kwd-group kwd-group-type="author" hwp:id="kwd-group-1"><title hwp:id="title-6">Keywords:</title><kwd hwp:id="kwd-1">Influenza viruses</kwd><kwd hwp:id="kwd-2">antivirals</kwd><kwd hwp:id="kwd-3">inhibitors of viral infection</kwd><kwd hwp:id="kwd-4">transcriptome</kwd><kwd hwp:id="kwd-5">host targeting, drug repurposing</kwd></kwd-group><counts><page-count count="69"/></counts></article-meta></front><body><sec id="s1" hwp:id="sec-5"><title hwp:id="title-7">Background</title><p hwp:id="p-7">Besides their well-known pandemic potential, annual outbreaks caused by influenza viruses account for several million respiratory infections and 250,000 to 500,000 deaths worldwide [<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">1</xref>]. This global high morbidity and mortality of influenza infections represents a major and recurrent public health threat with high economic burden. In this context, the suboptimal vaccine coverage and efficacy, coupled with recurrent events of viral resistance against a very limited antiviral portfolio, emphasize an urgent need for innovative treatment strategies presenting fewer obstacles for their clinical use [<xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-1" hwp:rel-id="ref-2">2</xref>].</p><p hwp:id="p-8">For decades, the strategy for antiviral development was mostly based on serial screenings of hundreds of thousands of molecules to identify “hits” and ‘leads” that target specific viral determinants, a quite costly and time-consuming process. However, the dramatic reduction in successful candidate identification over time [<xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-1" hwp:rel-id="ref-3">3</xref>], along with a concomitant increase of regulatory complexity to implement clinical trials, have fostered rising interest in novel strategies. Indeed, new approaches, focused on targeting the host instead of the virus, as well as on marketed drug repurposing for new antiviral indications [<xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-2" hwp:rel-id="ref-3">3</xref>–<xref ref-type="bibr" rid="c5" hwp:id="xref-ref-5-1" hwp:rel-id="ref-5">5</xref>] have been recently proposed in the context of global health emergencies posed by Ebola [<xref ref-type="bibr" rid="c6" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">6</xref>] and Zika [<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">7</xref>] viruses. Such innovative strategies are strongly supported by a shift of paradigms in drug discovery, from “one-drug-one-target” to “one-drug-multiple-targets” [<xref ref-type="bibr" rid="c8" hwp:id="xref-ref-8-1" hwp:rel-id="ref-8">8</xref>]. In that sense, different <italic toggle="yes">in silico</italic> approaches based on structural bioinformatic studies [<xref ref-type="bibr" rid="c9" hwp:id="xref-ref-9-1" hwp:rel-id="ref-9">9</xref>, <xref ref-type="bibr" rid="c10" hwp:id="xref-ref-10-1" hwp:rel-id="ref-10">10</xref>], systems biology approaches [<xref ref-type="bibr" rid="c11" hwp:id="xref-ref-11-1" hwp:rel-id="ref-11">11</xref>] and host gene expression analyses [<xref ref-type="bibr" rid="c12" hwp:id="xref-ref-12-1" hwp:rel-id="ref-12">12</xref>] have been applied to decipher multi-purpose effects of many US Food and Drug Administration (FDA)-approved drugs. Additionally, as successfully demonstrated in antiretroviral therapy [<xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-1" hwp:rel-id="ref-13">13</xref>], targeting host instead of viral determinants may confer a broad-spectrum antiviral efficacy, and also reduce the risk of emergence of drug resistance against influenza viruses [<xref ref-type="bibr" rid="c14" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">14</xref>]. As a result, the last decade has witnessed several host-directed experimental approaches against influenza infections, notably nitazoxanide, DAS181 or acetylsalicylic acid [<xref ref-type="bibr" rid="c15" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">15</xref>–<xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-1" hwp:rel-id="ref-17">17</xref>].</p><p hwp:id="p-9">In line with this emerging trend, we previously postulated that host global gene expression profiling can be considered as a “fingerprint” or signature of any specific cell state, including during infection or drug treatment, and hypothesized that the screening of databases for compounds that counteract virogenomic signatures could enable rapid identification of effective antivirals [<xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-1" hwp:rel-id="ref-18">18</xref>]. Based on this previous proof-of-concept obtained from <italic toggle="yes">in vitro</italic> gene expression profiles, we further improved our strategy by analyzing paired upper respiratory tract clinical samples collected during the acute infection and after recovery from a cohort of influenza A(H1N1)pdm09-infected patients and determined their respective transcriptomic signatures. We then performed an <italic toggle="yes">in silico</italic> drug screening using Connectivity Map (CMAP), the Broad Institute’s publicly available database of more than 7,000 drug-associated gene expression profiles [<xref ref-type="bibr" rid="c19" hwp:id="xref-ref-19-1" hwp:rel-id="ref-19">19</xref>, <xref ref-type="bibr" rid="c20" hwp:id="xref-ref-20-1" hwp:rel-id="ref-20">20</xref>], and identified a list of candidate bioactive molecules with signatures anti-correlated with those of the patient’s acute infection state (<bold><xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-1" hwp:rel-id="F1">Figure 1A</xref></bold>). The potential antiviral properties of selected FDA-approved molecules were firstly validated <italic toggle="yes">in vitro</italic>, and the most effective compounds were further compared to oseltamivir for the treatment of influenza A(H1N1)pdm09 virus infections in both C57BL/6 mice and 3D reconstituted human airway epithelia. Altogether, our results highlight diltiazem, a calcium channel blocker with so far undescribed capacity to stimulate the epithelial antiviral defense, as a promising repurposed host-targeted inhibitor of influenza infection. Moreover, our results plead in favor of the combination of diltiazem with the virus-targeted antiviral oseltamivir for the improvement of current anti-influenza therapy, and possibly decreasing the risk of antiviral resistance. This study confirms the feasibility and interest of integrating clinical virogenomic and chemogenomic inputs as part of a drug repurposing strategy to accelerate bedside-to-bench and bench-to-bedside drug development.</p><fig id="fig1" position="float" fig-type="figure" orientation="portrait" hwp:id="F1" hwp:rev-id="xref-fig-1-1 xref-fig-1-2 xref-fig-1-3 xref-fig-1-4 xref-fig-1-5 xref-fig-1-6 xref-fig-1-7 xref-fig-1-8 xref-fig-1-9"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>Fig. 1.</label><caption hwp:id="caption-1"><title hwp:id="title-8">From nasal wash clinical samples to a shortlist of 35 candidate molecules</title><p hwp:id="p-10"><bold>(A)</bold> Overview of the <italic toggle="yes">in silico</italic> strategy used in this study. A detailed description of the strategy is described in the Online Methods section. <bold>(B)</bold> Hierarchical clustering and heatmap of the 1,117 most differentially deregulated genes between “infected” (red) and “cured” (light green) samples. Raw median centered expression levels are color coded from blue to yellow. Dendrograms indicate the correlation between clinical samples (columns) or genes (rows). <bold>(C)</bold> Functional cross-analysis of candidate molecules obtained from Connectivity Map (CMAP). Three lists of candidate molecules were obtained using different set of genes in order to introduce functional bias and add more biological significance to this first screening: a Main List based on the complete list of differentially expressed genes, and two other lists (List #1 and #2) based on subsets of genes belonging to significantly enriched Gene Ontology (GO) terms. <bold>(D)</bold> Venn Diagram comparing the total 160 molecules obtained from the three lists described in (C), with monensin as the only common molecule. Only the candidates selected for <italic toggle="yes">in vitro</italic> screening and validation are depicted.</p></caption><graphic xlink:href="401315_fig1" position="float" orientation="portrait" hwp:id="graphic-1"/></fig></sec><sec id="s2" hwp:id="sec-6"><title hwp:id="title-9">Methods</title><sec id="s2a" hwp:id="sec-7"><title hwp:id="title-10">Clinical samples</title><p hwp:id="p-11">A previously published randomized clinical trial (ClinicalTrials.gov identifier <ext-link l:rel="related" l:ref-type="CLINTRIALGOV" l:ref="NCT00830323" ext-link-type="clintrialgov" xlink:href="NCT00830323" hwp:id="ext-link-1">NCT00830323</ext-link>) was conducted in Lyon and Paris (France) during the peak circulation of the influenza A(H1N1)pdm09 virus, with the aim to assess the efficacy of oseltamivir-zanamivir combination therapy compared with oseltamivir monotherapy [<xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-1" hwp:rel-id="ref-21">21</xref>]. Briefly, patients tested positive for influenza A infection by the QuickVue rapid antigen kit (Quidel) were randomized in one of the two treatment groups and nasal wash specimens were collected within two hours of the first visit and every 24 h until 96 h after treatment initiation. Nasal swabs were also performed on days 5 and 7. In voluntary patients, an optional supplementary nasal wash was performed at least three months after influenza infection (recovery phase). H1N1 subtype was further confirmed by PCR. For nine of these patients, transcriptomic data were obtained from paired samples collected during influenza infection without treatment and in the recovery phase.</p></sec><sec id="s2b" hwp:id="sec-8"><title hwp:id="title-11">Sample processing, RNA preparation and hybridization</title><p hwp:id="p-12">Nasal wash samples were collected in RNAlater<sup>®</sup> Stabilization Solution (Thermo Fisher Scientific). Total RNA was extracted using RNeasy Micro kit (Qiagen) following the manufacturer’s instructions. RNA quality was assessed using a Bioanalyzer2100 (Agilent technologies, Inc, Palo Alto, CA, USA). To account for samples having low amount and/or partially degraded RNA (RNA Integrity Numbers between 1 and 8), we applied two types of corrections: i) cRNA labelling was performed after a linear amplification protocol, as previously described [<xref ref-type="bibr" rid="c22" hwp:id="xref-ref-22-1" hwp:rel-id="ref-22">22</xref>] and ii) raw signals obtained after hybridization of labelled cRNA on microarray and data acquisition were processed using the MAXRS algorithm [<xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-1" hwp:rel-id="ref-23">23</xref>]. Labeled cRNA were hybridized on Affymetrix HG-U133plus2 microarrays according to manufacturer’s instructions in a GeneChip<sup>®</sup> Hybridization Oven 640 (Affymetrix) and microarrays were subsequently scanned in an Affymetrix 3000 7G scanner.</p></sec><sec id="s2c" hwp:id="sec-9"><title hwp:id="title-12">Data normalization &amp; MAXRS computational analysis</title><p hwp:id="p-13">The MAXRS algorithm [<xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-2" hwp:rel-id="ref-23">23</xref>] is particularly suited to gene expression analysis under low hybridization conditions. Briefly, this method takes advantage of the specific design of Affymetrix probe sets, which are composed of an average of 11 different probes that target the same locus, and is based on the observation that for most of the probe sets the same probe shows the highest fluorescence intensity in almost all arrays. For each microarray (m = 1..M) and for each probeset (t = 1..T), fluorescence intensity values on microarray m of all probes (p = 1..P<sub>t</sub>) belonging to the probeset t are sorted in increasing order. These ranks are denoted as r<sub>mtp</sub>. Then, we calculated across all microarrays the rank sum (RS<sub>tp</sub>) for each probeset t for each probe p belonging to the probeset t. Finally, for each probeset t, we kept the three probes p with the highest RS<sub>tp</sub>. The mean intensity of these three probes is attributed to the probeset t. As it is common practice with many modern pre-processing algorithms, and because of the low global fluorescence signal intensity, mismatched probes were excluded from MAXRS analysis.</p><p hwp:id="p-14">After pre-processing the raw dataset with the MAXRS algorithm, a normalization step was performed using Tukey median-polish algorithm [<xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-1" hwp:rel-id="ref-24">24</xref>]. Differential expression was assessed by applying a Student t-test for each probeset, and multiple testing was corrected using the Benjamini-Hochberg algorithm in the qvalue library [<xref ref-type="bibr" rid="c25" hwp:id="xref-ref-25-1" hwp:rel-id="ref-25">25</xref>]. For further downstream analysis, genes were selected according to two criteria: i) absolute fold change &gt;2, and ii) corrected p-value &lt;0.05. Data were generated according to the Minimum Information About a Microarray Experiment guidelines and deposited in the National Center for Biotechnology Information’s Gene Expression Omnibus [<xref ref-type="bibr" rid="c26" hwp:id="xref-ref-26-1" hwp:rel-id="ref-26">26</xref>] under accession number GSE93731.</p></sec><sec id="s2d" hwp:id="sec-10"><title hwp:id="title-13">Functional analysis</title><p hwp:id="p-15">Functional enrichment analysis was performed on a selection of differentially-expressed genes with DAVID tools [<xref ref-type="bibr" rid="c27" hwp:id="xref-ref-27-1" hwp:rel-id="ref-27">27</xref>], using the Gene Ontology (GO) [<xref ref-type="bibr" rid="c28" hwp:id="xref-ref-28-1" hwp:rel-id="ref-28">28</xref>]. To further select genes for the CMAP query, we selected 6 Biological Process terms (GO_BP: GO:0009615-response to virus; GO:0006955-immune response; GO:0042981-regulation of apoptosis; GO:0006952-defense response; GO:0009611-response to wounding; GO:0042127-regulation of cell proliferation) that shared &gt; 90% of genes with all significantly enriched GO_BP terms, and 3 relevant Cellular Component terms (GO_CC: GO:0031225-anchored to membrane; GO:0005829-cytosol; GO:0005654-nucleoplasm). To visualize and compare the different lists of compounds, Venn diagrams were obtained using the webtool developed by Dr. Van de Peer’s Lab at Ghent University (<ext-link l:rel="related" l:ref-type="uri" l:ref="http://bioinformatics.psb.ugent.be/webtools/Venn/" ext-link-type="uri" xlink:href="http://bioinformatics.psb.ugent.be/webtools/Venn/" hwp:id="ext-link-2">http://bioinformatics.psb.ugent.be/webtools/Venn/</ext-link>).</p></sec><sec id="s2e" hwp:id="sec-11"><title hwp:id="title-14">Cells and viruses</title><p hwp:id="p-16">Human lung epithelial A549 cells (ATCC CCL-185) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % fœtal calf serum and supplemented with 2 mM L-glutamine (Sigma Aldrich), penicillin (100 U/mL) and streptomycin (100 µg/mL) (Lonza), maintained at 37 °C and 5% CO<sub>2</sub>.</p><p hwp:id="p-17">Influenza viruses A/Lyon/969/09 and A/Quebec/144147/09 were produced in MDCK (ATCC CCL-34) cells in EMEM supplemented with 2 mM L-glutamine (Sigma Aldrich), penicillin (100 U/mL), streptomycin (100 µg/mL) (Lonza) and 1 µg/mL trypsin. Viral titers in plaque forming units (PFU/ml) and tissue culture infectious dose 50% (TCID50/mL) were determined in MDCK cells as previously described [<xref ref-type="bibr" rid="c29" hwp:id="xref-ref-29-1" hwp:rel-id="ref-29">29</xref>, <xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-1" hwp:rel-id="ref-30">30</xref>].</p></sec><sec id="s2f" hwp:id="sec-12"><title hwp:id="title-15">Viral growth assays</title><p hwp:id="p-18">For viral growth assays in the presence of molecules, A549 cells were seeded 24 h in advance in multi-well 6 plates at 1.8 x 10<sup>5</sup> cells/well. Three treatment protocols were evaluated. 1) In pre-treatment protocol, cells were washed with DMEM and then incubated with different concentrations of candidate molecules diluted in DMEM supplemented with 2 mM L-glutamine (Sigma Aldrich), penicillin (100 U/mL), streptomycin (100 µg/mL) (Lonza) and 0.5 µg/mL trypsin. Six hours after treatment, cells were washed and then infected with A/Lyon/969/09 (H1N1)pdm09 virus at a MOI of 0.1. 2) In pre-treatment plus post-treatment protocol, cells were initially treated and infected in the same conditions as explained above. One hour after viral infection, a second identical dose of candidate molecules in supplemented DMEM was added. 3) In post-treatment protocol, cells without pre-treatment were infected in the conditions described and treatments with candidate molecules at the indicated concentrations were initiated 24 h p.i. In all cases, supernatants were collected at 48 h p.i. and stored at -80 °C for TCID50/ml viral titration.</p></sec><sec id="s2g" hwp:id="sec-13"><title hwp:id="title-16">Viability and cytotoxicity assays</title><p hwp:id="p-19">Cell viability was measured using the CellTiter 96<sup>®</sup> AQueous One Solution Cell Proliferation Assay (MTS, Promega). A549 cells were seeded into 96-well plates and treated with different concentrations of molecules or solvents. Cells were incubated at 37 °C and 5% CO<sub>2</sub> and then harvested at different time-points, following the same scheme as in viral growth assays. Results were presented as a ratio of control values obtained with solvents. Treatment-related toxicity in human airway epithelia (HAE) was measured using the Cytotoxicity Detection Kit<sup>PLUS</sup> (LDH, Roche) according to the manufacturer’s instructions. Briefly, duplicate 100 µL-aliquots of basolateral medium from treated and control HAEs were incubated in the dark (room temperature, 30 minutes) with 100 µL of lactate dehydrogenase (LDH) reagent in 96-well plates. After incubation, “stop solution” was added and the absorbance was measured in a conventional microplate ELISA reader. The photometer was set up for dual readings to determine non-specific background at 750 nm, and absorbance was measured at 490 nm. Percent cytotoxicity was calculated as indicated by the manufacturer, using mock-treated and 1% triton-treated epithelia as “low” and “high” controls, respectively. Percent viability is presented as 100 – percent cytotoxicity.</p></sec><sec id="s2h" hwp:id="sec-14"><title hwp:id="title-17">Mouse model of viral infection</title><p hwp:id="p-20">All protocols were carried out in seven to nine-week old female C57BL/6N mice (Charles River, QC, Canada). Animals were randomized in groups of 15 according to their weight to ensure comparable median values on each group, and then housed in micro-isolator cages (5 animals per cage) in a biosafety 2 controlled environment (22 °C, 40% humidity, 12:12 h photoperiods), with <italic toggle="yes">ad libitum</italic> access to food and water.</p><p hwp:id="p-21">On day 0, mice were lightly anesthetized with inhaled 3% isoflurane/oxygen, and then infected by intranasal (i.n.) instillation of influenza A/Quebec/144147/09 (H1N1)pdm09 virus in 30 µl of saline, as specified in each case. Control animals were mock-infected with 30 µl of saline. Candidate molecules were evaluated in two different treatment protocols: i) treatments were started on the same day of infection (day 0, 6 h prior to infection), or ii) treatments were started 24 h after infection (day 1). Regardless of treatment initiation time, all treatments were performed <italic toggle="yes">per os</italic> (150-µl gavage) once daily for 5 consecutive days (5 drug administrations in total). Mortality, body weight and clinical signs such as lethargy and ruffled fur were daily monitored on 10 animals/group for a total of 14 days. Animals were euthanized if they reached the humane endpoint of &gt;20% weight loss. The remaining 5 animals/group were euthanized on day 5 p.i. to measure LVTs.</p><p hwp:id="p-22">Vehicle (saline) or oseltamivir were used as placebo and positive treatment control, respectively. The oseltamivir dose (10 mg/kg/day) was adjusted to confer ∼50% protection in the selected experimental conditions and is considered a good correlate of half the normal dose of 150 mg/day given to humans [<xref ref-type="bibr" rid="c31" hwp:id="xref-ref-31-1" hwp:rel-id="ref-31">31</xref>]. The doses of repurposed candidate molecules were selected to be in the non-toxic range for mouse studies, according to published preclinical data for their first therapeutic indication. To validate this choice in our specific model, potential drug toxicity was evaluated in mock-infected animals treated with the same regimens as virus-infected mice.</p></sec><sec id="s2i" hwp:id="sec-15"><title hwp:id="title-18">Pulmonary viral titers</title><p hwp:id="p-23">In order to evaluate the effect of different treatments on viral replication, 5 animals per group were euthanized on day 5 p.i. and lungs were removed aseptically. Mice were randomly selected from the 3 cages of each group to minimize cage-related bias. Lungs were homogenized in 1 ml of PBS using a bead mill homogenizer (Tissue Lyser, Qiagen) and debris was pelleted by centrifugation (2,000 g, 5 min). Triplicate 10-fold serial dilutions of each supernatant were plated on ST6GalIMDCK cells (kindly provided by Dr. Y. Kawaoka, University of Wisconsin, Madison, WI) and titrated by plaque assays [<xref ref-type="bibr" rid="c29" hwp:id="xref-ref-29-2" hwp:rel-id="ref-29">29</xref>]. The investigator was blinded to group allocation.</p></sec><sec id="s2j" hwp:id="sec-16"><title hwp:id="title-19">Viral infection in reconstituted human airway epithelium (HAE)</title><p hwp:id="p-24">MucilAir<sup>®</sup> HAE were obtained from Epithelix SARL (Geneva, Switzerland) and maintained in air-liquid interphase with specific culture medium in Costar Transwell inserts (Corning, NY, USA) according to manufacturer’s instructions. For infection experiments, apical poles were gently washed with warm PBS and then infected with a 100-µL dilution of influenza A/Lyon/969/09 (H1N1)pdm09 virus in OptiMEM medium (Gibco, ThermoFisher Scientific) at a MOI of 0.1. Basolateral pole sampling as well as 150-µL OptiMEM apical washes were performed at the indicated time points, and then stored at -80 °C for PFU/mL and TCID50/mL viral titration. Treatments with specific dilutions of candidate molecules alone or combined with oseltamivir in MucilAir<sup>®</sup> culture medium were applied through basolateral poles. All treatments were initiated on day 0 (5 h after viral infection) and continued once daily for 5 consecutive days (5 drug administrations in total). Variations in transepithelial electrical resistance (Δ TEER) were measured using a dedicated volt-ohm meter (EVOM2, Epithelial Volt/Ohm Meter for TEER) and expressed as Ohm/cm<sup>2</sup>.</p></sec><sec id="s2k" hwp:id="sec-17"><title hwp:id="title-20">High throughput sequencing and bioinformatics analysis</title><p hwp:id="p-25">cDNA libraries were prepared from 200 ng of total RNA using the Scriptseq™ complete Gold kit-Low Input (SCL6EP, Epicentre), according to manufacturer’s instructions. Each cDNA library was amplified and indexed with primers provided in the ScriptSeq™ Index PCR Primers kit (RSBC10948, Epicentre) and then sequenced as 100 bp paired-end reads. Prior to sequencing, libraries were quantified with QuBit and Bioanalyzer2100, and indexed libraries were pooled in equimolar concentrations. Sequencing was performed on an Illumina HiSeq 2500 system (Illumina, Carlsbad, CA), with a required minimum of 40 million reads sequenced per sample. Conversion and demultiplexing of reads was performed using bcl2fastq 1.8.4 (Illumina). The FastQC software (<ext-link l:rel="related" l:ref-type="uri" l:ref="http://www.bioinformatics.babraham.ac.uk/projects/fastqc" ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc" hwp:id="ext-link-3">http://www.bioinformatics.babraham.ac.uk/projects/fastqc</ext-link>) was used for quality controls of the raw data. Reads were trimmed using the Trimmomatic [<xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-1" hwp:rel-id="ref-32">32</xref>] software, with a minimum quality threshold of Q30. Trimmed reads were pseudo-aligned to the <italic toggle="yes">Homo sapiens</italic> genome (GRCh38.p11) using the Kallisto software [<xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-1" hwp:rel-id="ref-33">33</xref>]. Statistical analysis was performed in R3.3.1 with the package EdgeR 3.14.0 [<xref ref-type="bibr" rid="c34" hwp:id="xref-ref-34-1" hwp:rel-id="ref-34">34</xref>]. Differential expression was calculated by comparing each condition to the mock using a linear model. The Benjamini-Hochberg procedure was used to control the false discovery rate (FDR). Transcripts with an absolute fold change &gt;2 and a corrected p-value &lt;0.05 were considered to be differentially expressed. Enriched pathways and GO terms were assessed with DAVID 6.8 [<xref ref-type="bibr" rid="c27" hwp:id="xref-ref-27-2" hwp:rel-id="ref-27">27</xref>]. For visualization purposes, a heatmap and stacked barplots were constructed in R3.3.1 on mean-weighted fold changes and association between conditions were assessed by Spearman correlation analysis.</p></sec><sec id="s2l" hwp:id="sec-18"><title hwp:id="title-21">Statistical analysis</title><p hwp:id="p-26">All experimental assays were performed in duplicate at a minimum, and representative results are shown unless indicated otherwise. No statistical methods were used to predetermine sample size in animal studies, which were estimated according to previous studies and the known variability of the assays. No mice were excluded from post-protocol analyses, the experimental unit was an individual animal and equal variance was assumed. Kaplan-Meier survival plots were compared by Log-Rank (Mantel-Cox) test and hazard ratios (HR) were computed by the Mantel-Haenszel method. Weight loss and viral titers of all groups were compared by one-way analysis of variance (ANOVA) with Tukey’s multiple comparison post-test. The testing level (α) was 0.05. Statistical analyses were performed on all available data, using GraphPad, Prism 7.</p></sec></sec><sec id="s3" hwp:id="sec-19"><title hwp:id="title-22">Results</title><sec id="s3a" hwp:id="sec-20"><title hwp:id="title-23">Generation of clinical virogenomic profiles</title><p hwp:id="p-27">We determined <italic toggle="yes">in vivo</italic> transcriptional signatures of infection from paired nasal wash samples of nine untreated patients, collected during acute A(H1N1)pdm09 pandemic influenza infection (“infected”) and at least three months later to ensure a recovery non-infected state (“cured”) [<xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-2" hwp:rel-id="ref-21">21</xref>]. The nine patients from whom transcriptomic data could be obtained constitute a representative sample of the whole studied cohort, except for the male sex ratio (<bold>Table S1</bold>). We combined two strategies to tackle the characteristic low RNA amount/quality of this type of clinical samples. Firstly, cRNA labelling was performed after a linear amplification of initial RNA, as previously described [<xref ref-type="bibr" rid="c35" hwp:id="xref-ref-35-1" hwp:rel-id="ref-35">35</xref>]. Secondly, raw signals obtained after hybridization of labelled cRNA on microarray and data acquisition were processed using the MAXRS algorithm [<xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-3" hwp:rel-id="ref-23">23</xref>] to overcome low hybridization conditions. This approach, initially developed for the analysis of heterologous hybridizations, takes advantage of the specific design of the Affymetrix<sup>®</sup> microarray used in our study, with several probes targeting the same locus [<xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-4" hwp:rel-id="ref-23">23</xref>].</p><p hwp:id="p-28">After normalization, differentially expressed genes were selected based on two criteria: i) an absolute fold change &gt;2, and ii) a Benjamini-Hochberg corrected p-value &lt;0.05. We therefore identified a total of 1,117 commonly deregulated probes, with almost equal proportion of up-regulated (48.4%; n=541) and down-regulated probes (51.7%; n=576). Remarkably, despite considerable inter-patient variability among recovery state samples, a substantial homogenization of transcriptional profiles was observed in the context of infection, as shown in the heatmap presented in <bold><xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-2" hwp:rel-id="F1">Figure 1B</xref></bold> and by the median Spearman’s ρ correlation values for both groups (0.60 “cured” vs. 0.90 “infected”). These virogenomic signatures of infection constituted the input for the subsequent <italic toggle="yes">in silico</italic> query for the identification of candidate compounds.</p></sec><sec id="s3b" hwp:id="sec-21"><title hwp:id="title-24"><italic toggle="yes">In silico</italic> cross-analysis of chemogenomic versus virogenomic clinical profiles</title><p hwp:id="p-29">We then performed an <italic toggle="yes">in-silico</italic> search for molecules that reverse the virogenomic signature of infection, using the CMAP database (Build 02) as previously described [<xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-2" hwp:rel-id="ref-18">18</xref>]. CMAP is a collection of genome-wide transcriptional expression data from cultured human cells treated with bioactive small molecules. HG-U133plus2 probesets were mapped to the U133A probesets using the Ensembl BioMarts online tool [<xref ref-type="bibr" rid="c36" hwp:id="xref-ref-36-1" hwp:rel-id="ref-36">36</xref>, <xref ref-type="bibr" rid="c37" hwp:id="xref-ref-37-1" hwp:rel-id="ref-37">37</xref>], and connectivity scores and p-values were obtained using the CMAP algorithm [<xref ref-type="bibr" rid="c19" hwp:id="xref-ref-19-2" hwp:rel-id="ref-19">19</xref>, <xref ref-type="bibr" rid="c20" hwp:id="xref-ref-20-2" hwp:rel-id="ref-20">20</xref>]. With the global set of 1,000 most differentially expressed genes as input (<bold><xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-3" hwp:rel-id="F1">Figure 1C</xref></bold>, Main List), we obtained a preliminary list of 60 candidate compounds. In parallel, we used two other subsets of genes belonging to significantly enriched Gene Ontology (GO) terms obtained from microarray analyses to introduce functional bias and add more biological significance to our first screening. Hence, by using 6 Biological Process terms (GO_BP) that shared more than 90% of genes (<bold><xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-4" hwp:rel-id="F1">Figure 1C</xref></bold>, Functional cross-analysis #1), a second list of 109 compound candidates was obtained. A third list of 19 compounds was obtained using 3 relevant Cellular Component terms (GO_CC) (<bold><xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-5" hwp:rel-id="F1">Figure 1C</xref></bold>, Functional cross-analysis #2). The comparison of the 160 compounds from the three distinct lists (12.2% of compounds of CMAP, <bold>Table S2</bold>) highlighted monensin as the only common compound (<bold><xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-6" hwp:rel-id="F1">Figure 1D</xref></bold>).</p><p hwp:id="p-30">To rationally reduce the number of drug candidates, bioactive drugs were excluded if not compatible with a final use as antiviral, mostly for safety (e.g. teratogens, intercalating agents) and/or pharmacological (e.g. documented low bioavailability) reasons, based on clinical data and the PubMed/PubChem databases. Thus, the number of candidates was initially decreased to 139 and then to 110 (<bold><xref rid="figS1" ref-type="fig" hwp:id="xref-fig-7-1" hwp:rel-id="F7">Figure S1</xref></bold>). We subsequently determined a shortlist of 35 bioactive molecules (&lt;3% of CMAP, <bold><xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-1" hwp:rel-id="T1">Table 1</xref></bold>) for <italic toggle="yes">in vitro</italic> screening, based on two main criteria: i) molecules representative of the different pharmacological classes identified, and ii) molecules evenly distributed in the three lists obtained after <italic toggle="yes">in silico</italic> screening (Main List, List #1 and List #2, <bold><xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-7" hwp:rel-id="F1">Figure 1D</xref></bold>), which comprise a panoply of documented pharmacological classes, including anti-fungal agents (e.g. monensin, flucytosine), anti-inflammatory agents (e.g. felbinac, apigenin, prednisone) and adrenergic agonists/antagonists (timolol, methoxamine, tolazoline), as represented in the Venn diagram (<bold><xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-8" hwp:rel-id="F1">Figure 1D</xref></bold>, <bold><xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-2" hwp:rel-id="T1">Table 1</xref></bold>). Interestingly, at least 14 (40%) molecules from our short-list belong to a pharmacological class related with anti-microbial or anti-inflammatory activities (<bold><xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-3" hwp:rel-id="T1">Table 1</xref></bold>, #), and 11 (31.4%) have already been reported in the literature for their antiviral properties against influenza or other viruses (<bold><xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-4" hwp:rel-id="T1">Table 1</xref></bold>, *), notably the nucleoside inhibitor ribavirin [<xref ref-type="bibr" rid="c38" hwp:id="xref-ref-38-1" hwp:rel-id="ref-38">38</xref>, <xref ref-type="bibr" rid="c39" hwp:id="xref-ref-39-1" hwp:rel-id="ref-39">39</xref>] and the ionophore monensin [<xref ref-type="bibr" rid="c40" hwp:id="xref-ref-40-1" hwp:rel-id="ref-40">40</xref>].</p><table-wrap id="tbl1" orientation="portrait" position="float" hwp:id="T1" hwp:rev-id="xref-table-wrap-1-1 xref-table-wrap-1-2 xref-table-wrap-1-3 xref-table-wrap-1-4 xref-table-wrap-1-5"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/TBL1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T1</object-id><object-id pub-id-type="publisher-id">tbl1</object-id><label>Table 1.</label><caption hwp:id="caption-2"><title hwp:id="title-25">Shortlist of the 35 selected molecules and their documented pharmacological classes.</title><p hwp:id="p-31">Shortlist of the 35 selected candidates representative of the 110 molecules obtained from the <italic toggle="yes">in silico</italic> screening (<xref rid="fig1" ref-type="fig" hwp:id="xref-fig-1-9" hwp:rel-id="F1">Fig 1</xref> and S1). Documented pharmacological classes were obtained from PubChem (<ext-link l:rel="related" l:ref-type="uri" l:ref="https://pubchem.ncbi.nlm.nih.gov" ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov" hwp:id="ext-link-4">https://pubchem.ncbi.nlm.nih.gov</ext-link>). Asterisks (*) indicate molecules previously evaluated for their antiviral properties according to the literature, and numerals (#) those belonging to anti-microbial or anti-inflammatory related pharmacological classes</p></caption><graphic xlink:href="401315_tbl1" position="float" orientation="portrait" hwp:id="graphic-2"/></table-wrap></sec><sec id="s3c" hwp:id="sec-22"><title hwp:id="title-26">Inhibitory effect of the selected molecules on A(H1N1)pdm09 viral growth <italic toggle="yes">in vitro</italic></title><p hwp:id="p-32"><italic toggle="yes">In vitro</italic> screening of the antiviral potency of the 35 selected molecules was performed in A549 human lung epithelial cells seeded in 6-well plates. Firstly, we evaluated the impact of 6 h pre-treatment with a 10-fold drug concentration range, using the original CMAP concentration as reference. Six hours after treatment, cells were washed and infected with influenza A(H1N1)pdm09 virus at a multiplicity of infection (MOI) of 0.1. Viral titers in supernatants collected from treated samples at 48 h post infection (p.i.) were normalized with those measured in mock-treated controls (&gt;10<sup>5</sup> TCID50/mL). Potential treatment-induced cell toxicity was evaluated in the same experimental conditions using the MTS assay and expressed also as the percentage of cell viability compared to non-infected controls (<bold><xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-1" hwp:rel-id="F2">Figure 2</xref></bold>). Based on antiviral activity and cell viability profiles obtained (<bold><xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-2" hwp:rel-id="F2">Figure 2A</xref></bold>, blue triangles), we defined as “inhibitors” compounds that fulfilled the following two criteria: i) induce &gt;75% reduction on viral production, and ii) have minor impact on cell viability, with relative values in the 90%-110% range (<bold><xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-3" hwp:rel-id="F2">Figure 2A</xref></bold>, squares in <bold>left panels</bold> and zooms in <bold>right panels</bold>). A total of 10 compounds (28.6%) matched both criteria, mainly when used at a 10-fold CMAP concentration (<bold><xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-4" hwp:rel-id="F2">Figure 2B</xref></bold>), yet only a limited number of them exhibited classic dose-dependent inhibition. Whenever possible, as in the case of monensin or ranitidine for example, EC50 values were calculated, which were mostly in the micromolar range (<bold><xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-5" hwp:rel-id="F2">Figure 2B</xref></bold>).</p><p hwp:id="p-33">In a second round of screening, we tested the same 6 h pre-treatment but with serial 10-fold dilutions from the initial CMAP concentration to CMAP/10,000, followed by one additional treatment immediately after infection (<bold><xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-6" hwp:rel-id="F2">Figure 2A</xref></bold>, green circles in <bold>left</bold> and <bold>right panels</bold>). In these conditions, 30 compounds (85.7%) met our criteria to be considered as inhibitors of viral production (<bold><xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-7" hwp:rel-id="F2">Figure 2C</xref></bold>), with half of them showing a classic dose-dependent inhibition effect. Calculated EC50 values were in the nanomolar range and hence significantly lower than those calculated in the context of pre-treatment only. Dose response curves and calculated EC50 for all the 35 compounds are presented in <bold><xref rid="figS2" ref-type="fig" hwp:id="xref-fig-8-1" hwp:rel-id="F8">Figure S2</xref></bold> and <bold>Table S3</bold>, respectively.</p><fig id="fig2" position="float" fig-type="figure" orientation="portrait" hwp:id="F2" hwp:rev-id="xref-fig-2-1 xref-fig-2-2 xref-fig-2-3 xref-fig-2-4 xref-fig-2-5 xref-fig-2-6 xref-fig-2-7 xref-fig-2-8"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>Fig. 2.</label><caption hwp:id="caption-3"><title hwp:id="title-27">Screening and validation of the effect of selected molecules on A(H1N1)pdm09 viral growth <italic toggle="yes">in vitro</italic>.</title><p hwp:id="p-34"><bold>(A, left)</bold> Evaluation on A549 cells of the antiviral potency of the 35 candidates selected by <italic toggle="yes">in silico</italic> analysis. Relative viral production (%, X axis) and relative cell viability (%, Y axis) of both pre-treatment (blue triangles) and pre-treatment/treatment (green circles) regimens were evaluated. A 10-fold drug concentration range using CMAP as reference (CMAP x10, CMAP, CMAP/10, CMAP/100, CMAP/1,000 and CMAP/10,000) was used. CMAPx10 was only tested in the context of pre-treatment, by anticipation of a lower efficacy of molecules in this experimental setup. All experimental assays were performed in triplicate and mean values are represented. <bold>(A, right)</bold> Zoom panels depicting molecules defined as “inhibitors” according to the following two criteria: i) induce a 75% or higher reduction on viral production, and ii) have minor impact on cell viability, with relative values in the 90%-110% range. For clarity purposes, with the exception of diltiazem, etilefrine, monensin and ribavirin, abbreviations were used: Adiphenine "Ad”; Alpha-estradiol "Al"; Amiloride "Am"; Apigenin "Ap"; Benzathine Benzylpenicilline "Be"; Biperiden "Bi"; Carmustine "Ca"; Chloropyramine "Ch"; Clofidium tosylate "Cl"; Diphenydramine "Di"; Felbinac "Fe"; Flucytosine "Fl"; Folic acid "Fo"; Fusidic acid "Fu"; Genistein "Ge"; Gentamycin "Ga"; Lanatoside C "La"; Levamisole "Le"; Methoxamine "Me"; Nimesulide "Ni"; Pindolol "Pi"; Prednisone "Po"; Prestwick-1103 "Pr"; Ranitidine "Ra"; Riboflavine "Ri"; Roxythromycin "Ro"; Sulfadimethoxine "Sud"; Sulfamonomethoxine "Sum"; Timolol "Ti"; Tolazoline "To"; Urseodeoxycholic acid "Us". Dose-response curves for all the 35 molecules are presented in <xref rid="tblS3" ref-type="table" hwp:id="xref-table-wrap-4-1" hwp:rel-id="T4">Supplementary Table 3</xref>. <bold>(B)</bold> Venn diagram of the 10 molecules identified in pre-treatment (10/35; 28.57%) and matching the “inhibitor” criteria, mainly when used at 10-fold CMAP concentration. EC50 curves for monensin and ranitidine are represented. <bold>(C)</bold> Venn diagram of the 30 “inhibitor” molecules identified in pre-treatment/treatment (30/35; 85.7%). EC50 curves for monensin, diltiazem and etilefrine are represented.</p></caption><graphic xlink:href="401315_fig2" position="float" orientation="portrait" hwp:id="graphic-3"/></fig></sec><sec id="s3d" hwp:id="sec-23"><title hwp:id="title-28">Efficacy of selected molecules for the treatment of influenza A(H1N1)pdm09 virus infection in mice</title><p hwp:id="p-35">Based on EC50 and cytoxicity data from the <italic toggle="yes">in vitro</italic> screening, we selected 8 molecules to investigate their potential as inhibitors of influenza A(H1N1)pdm09 in C57BL/6 mice. Oseltamivir, the standard antiviral for the treatment of influenza infections was used as control. All treatments were performed <italic toggle="yes">per os</italic>, starting 6 h before infection and being continued once daily for 5 consecutive days (5 drug administrations in total) (<bold><xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-1" hwp:rel-id="F3">Figure 3</xref></bold>). While animals treated with oseltamivir or monensin showed clinical improvement compared to the saline (placebo) group in terms of survival and weight loss (oseltamivir only), treatment with Lanatoside C, prednisolone, flucytosine, felbinac and timolol showed no clinical benefit at the selected concentrations (<bold>Figure S5A</bold>). In contrast, diltiazem and etilefrine not only significantly improved survival and maximum mean weight losses (<bold><xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-2" hwp:rel-id="F3">Figure 3A</xref></bold>-<bold>B</bold>), but also showed at least 1-log reductions in lung viral titers (LVTs) on day 5 p.i. (<bold><xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-3" hwp:rel-id="F3">Figure 3C</xref></bold>). Importantly, no signs of toxicity were observed for any of the drugs at the regimens tested (<bold><xref rid="figS3" ref-type="fig" hwp:id="xref-fig-9-1" hwp:rel-id="F9">Figure S3B</xref></bold>).</p><fig id="fig3" position="float" fig-type="figure" orientation="portrait" hwp:id="F3" hwp:rev-id="xref-fig-3-1 xref-fig-3-2 xref-fig-3-3 xref-fig-3-4"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/FIG3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F3</object-id><object-id pub-id-type="publisher-id">fig3</object-id><label>Fig. 3.</label><caption hwp:id="caption-4"><title hwp:id="title-29">Efficacy of oral administration of selected molecules in mice infected with influenza A(H1N1)pdm09 virus.</title><p hwp:id="p-36">C57BL/6N mice (n=15/group) were intranasally inoculated with 5 x 10<sup>5</sup> PFU of influenza A/Quebec/144147/09 virus on day 0 and treated by gavage with saline (grey), oseltamivir 10 mg/kg/day (red), monensin 10 mg/kg/day (blue), diltiazem 90 mg/kg/day (green), or etilefrine 3 mg/kg/day (orange). A mock-infected, saline-treated group (black dotted line, n=6) was included as control. Treatments were initiated on day 0 (6 h before infection) and administered once daily for 5 consecutive days. <bold>(A)</bold> Survival rates (n=10/group), <bold>(B)</bold> mean weight changes (±SEM, n=10/group or remaining mice) and <bold>(C)</bold> median (±CI95, n=5/group) lung viral titers on day 5 p.i. are shown. *p&lt;0.05, **p&lt;0.01 and ***p&lt;0.001 compared to the infected saline-treated group by one-way ANOVA with Tukey’s post-test. Data are representative of two independent experiments.</p></caption><graphic xlink:href="401315_fig3" position="float" orientation="portrait" hwp:id="graphic-4"/></fig></sec><sec id="s3e" hwp:id="sec-24"><title hwp:id="title-30">Diltiazem retains its <italic toggle="yes">in vivo</italic> efficacy when administered 24 h after viral infection</title><p hwp:id="p-37">To best mimic the therapeutic setting, we next evaluated the efficacy of the same 5-day oral regimen with diltiazem or etilefrine but when initiated 24 h after viral infection (<bold><xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-1" hwp:rel-id="F4">Figure 4</xref></bold>). As with oseltamivir and monensin, diltiazem treatment completely prevented mortality and reduced weight loss in influenza A(H1N1)pdm09 infected mice, which otherwise showed only 50% (5/10) survival for the etilefrine and saline groups (<bold><xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-2" hwp:rel-id="F4">Figure 4A-B</xref></bold>). Interestingly, 1-to 1.5-log reductions in LVTs compared to the saline group were observed at day 5 in groups of mice treated with diltiazem or etilefrine (<bold><xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-3" hwp:rel-id="F4">Figure 4C</xref></bold>). We then used a more stringent approach by increasing the viral inoculum to evaluate the same delayed (24 h post infection) 5-day diltiazem regimen in the context of a 100% lethal A(H1N1)pdm09 infection (<bold><xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-4" hwp:rel-id="F4">Figure 4D-F</xref></bold>). Whereas treatment with oseltamivir and diltiazem successfully rescued 40% (4/10) and 20% (2/10) of mice, respectively, half-dose treatment with diltiazem (45 mg/kg) rescued 30% (3/10) of mice from death, also showing significant improvement in mean weight loss (<bold><xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-5" hwp:rel-id="F4">Figure 4D-E</xref></bold>). Calculated hazard ratios (HR) for the saline group compared to these three treatment groups were 8.41 (CI95: 1.65-43.02), 2.85 (0.56-14.47) and 7.62 (1.49-38.96), respectively. Noteworthy, LVTs at day 5 p.i. were comparable among all treated and untreated groups (<bold><xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-6" hwp:rel-id="F4">Figure 4F</xref></bold>), suggesting mainly a protective effect of diltiazem towards severe influenza infection rather than a direct role in decreasing viral production.</p><fig id="fig4" position="float" fig-type="figure" orientation="portrait" hwp:id="F4" hwp:rev-id="xref-fig-4-1 xref-fig-4-2 xref-fig-4-3 xref-fig-4-4 xref-fig-4-5 xref-fig-4-6 xref-fig-4-7 xref-fig-4-8"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/FIG4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F4</object-id><object-id pub-id-type="publisher-id">fig4</object-id><label>Fig. 4.</label><caption hwp:id="caption-5"><title hwp:id="title-31">Efficacy of post-infection oral treatment with diltiazem and etilefrine in mice infected with influenza A(H1N1)pdm09 virus.</title><p hwp:id="p-38">C57BL/6N mice (n=15/group) were intranasally inoculated with 1 x 10<sup>5</sup> <bold>(A</bold>-<bold>C)</bold> or 4 x 10<sup>6</sup> <bold>(D</bold>-<bold>F)</bold> PFU of influenza A/Quebec/144147/09 virus on day 0 and treated by gavage with saline (grey), oseltamivir 10 mg/kg/day (red), monensin 10 mg/kg/day (blue, A only), diltiazem 45 mg/kg/day (light green, B only), diltiazem 90 mg/kg/day (dark green), or etilefrine 3 mg/kg/day (orange, A only). A mock-infected, saline-treated group (black dotted line, n=6) was included as control. Treatments were initiated on day 1 (24 h after infection and administered once daily for 5 consecutive days. <bold>(A</bold>, <bold>D)</bold> Survival rates (n=10/group), <bold>(B</bold>, <bold>E)</bold> mean weight changes (±SEM, n=10/group or remaining mice), and <bold>(C</bold>, <bold>F)</bold> median (±CI95, n=5/group) lung viral titers on day 5 p.i. are shown. *p&lt;0.05, **p&lt;0.01 and ***p&lt;0.001 compared to the infected saline-treated group by one-way ANOVA with Tukey’s post-test. Data are representative of two independent experiments.</p></caption><graphic xlink:href="401315_fig4" position="float" orientation="portrait" hwp:id="graphic-5"/></fig></sec><sec id="s3f" hwp:id="sec-25"><title hwp:id="title-32">Diltiazem significantly reduces viral replication in infected reconstituted human airway epithelia (HAE)</title><p hwp:id="p-39">To further complement <italic toggle="yes">in vivo</italic> data, we characterized the inhibitory properties of diltiazem using a biologically relevant reconstituted airway epithelium model, derived from human primary bronchial cells (MucilAir<sup>®</sup>, Epithelix). HAE were infected with influenza A(H1N1)pdm09 at a MOI of 0.1, and treatments on the basolateral medium were initiated 5 h p.i. and continued once daily for 5 consecutive days. In the absence of treatment, viral replication at the apical surface peaked at 48 h p.i. (∼1 x 10<sup>8</sup> PFU/ml) and was detectable at important levels for at least 7 days. As expected, trans-epithelial electrical resistance (TEER) values, measuring tight junction and cell layer integrity, sharply decreased and bottomed out at 72 h p.i. in the untreated control, correlating with the first virus detection on the basolateral medium (<bold><xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-1" hwp:rel-id="F5">Figure 5A</xref></bold> and <bold>Table S6</bold>). A similar pattern was observed in infected HAE treated with oseltamivir 0.1 μM or diltiazem 9 μM (CMAP), which conferred no significant advantage over the untreated control. Conversely, oseltamivir 1 μM and diltiazem 90 μM treatments (10-fold CMAP) strongly inhibited viral replication, delaying the peak of viral production by 24 h. Both treatments induced &gt;3-log reductions in apical viral titers at 48 h p.i. compared to the untreated control, and &gt;2-log reductions when comparing peak titers (48 h p.i. untreated vs. 72 h p.i. treated). Moreover, whereas oseltamivir treatment stabilized TEER during the time-course of infection, diltiazem treatment partially buffered the TEER decrease observed in the untreated control (<bold><xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-2" hwp:rel-id="F5">Figure 5A</xref></bold> and <bold>Table S6</bold>). No virus was detected on the basolateral medium for these two treated groups, and absence of treatment-induced toxicity was confirmed by measuring the release of intracellular lactate dehydrogenase (LDH). Interestingly, we observed that inhibitory and protective properties demonstrated by diltiazem were progressively reversible when basolateral medium was replaced with fresh medium without drugs. Overall, these results are in accordance and strongly support the inhibitory and protective effects of diltiazem observed <italic toggle="yes">in vitro</italic> and in mice, respectively.</p><fig id="fig5" position="float" fig-type="figure" orientation="portrait" hwp:id="F5" hwp:rev-id="xref-fig-5-1 xref-fig-5-2 xref-fig-5-3 xref-fig-5-4 xref-fig-5-5 xref-fig-5-6"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/FIG5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F5</object-id><object-id pub-id-type="publisher-id">fig5</object-id><label>Fig. 5.</label><caption hwp:id="caption-6"><title hwp:id="title-33">Diltiazem significantly reduces viral replication in infected reconstituted human airway epithelia (HAE).</title><p hwp:id="p-40">Apical viral production (±SEM) and transepithelial electrical resistance (Δ TEER±SEM) in MucilAir<sup>®</sup> human airway epithelium infected on the apical pole with influenza A/Lyon/969/09 (H1N1)pdm09 virus at a MOI of 0.1 and subjected to <bold>(A)</bold> single or <bold>(B)</bold> combined treatments by the basolateral pole. Treatments with culture medium (mock, grey), oseltamivir 0.1 µM (red, dotted line), oseltamivir 1 µM (red, solid line), diltiazem 9 µM (green, dotted line), diltiazem 90 µM (green, solid line), oseltamivir 0.1 µM / diltiazem 9 µM (brown, dotted line) or oseltamivir 1 µM / diltiazem 90 µM (brown, solid line) were initiated 5 h after infection and administered once daily for 5 consecutive days. *p&lt;0.05, **p&lt;0.01 and ***p&lt;0.001 compared to the infected mock-treated group by one-way ANOVA with Tukey’s post-test. Data are representative of three independent experiments.</p></caption><graphic xlink:href="401315_fig5" position="float" orientation="portrait" hwp:id="graphic-6"/></fig></sec><sec id="s3g" hwp:id="sec-26"><title hwp:id="title-34">Diltiazem-oseltamivir combination confers improved efficacy when compared to monotherapy in infected HAE</title><p hwp:id="p-41">We anticipated that the combination of two antiviral compounds that target different viral/cellular determinants could induce better virological and physiological responses when compared to antiviral monotherapy. We therefore evaluated the diltiazem-oseltamivir combination in the same conditions described above, notably a 5-day treatment course with treatment initiation at 5 h p.i. The diltiazem 90 μM / oseltamivir 1 μM combination conferred &gt;3-log reduction in apical peak viral titers when compared to the untreated control, even greater than that observed with same dose monotherapy. TEER values remained stable during combined treatment, comparable to those observed with oseltamivir 1 μM monotherapy (<bold><xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-3" hwp:rel-id="F5">Figure 5B</xref></bold> and <bold>Table S6</bold>). Remarkably, although not effective as monotherapy in the low concentrations tested above, the diltiazem 9 μM / oseltamivir 0.1 μM combination contrariwise delayed the peak of viral production, significantly reduced apical viral titers, and slightly buffered TEER values compared to the untreated control (<bold><xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-4" hwp:rel-id="F5">Figure 5B</xref></bold> and <bold>Table S6</bold>). Once again, no treatment-related toxicity was observed for any of the combinations tested. These results plead in favor of the potential of diltiazem for the improvement of current anti-influenza therapy with neuraminidase inhibitors.</p></sec><sec id="s3h" hwp:id="sec-27"><title hwp:id="title-35">Diltiazem treatment induces a significant reversion of the viral infection signature</title><p hwp:id="p-42">Since the rationale behind our approach relies on attaining antiviral activity through a drug-induced global and multi-level inversion of the infection signature, we advantageously used the MucilAir<sup>®</sup> HAE model coupled with high-throughput sequencing in order to characterize and compare the specific transcriptional signatures induced by infection and/or diltiazem treatment (<bold><xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-1" hwp:rel-id="F6">Figures 6</xref> and S4</bold>). HAE were mock-infected or infected with influenza A(H1N1)pdm09 virus and then mock-treated or treated in the same experimental conditions in which the antiviral effect of diltiazem has been previously validated (MOI of 0.1, 90 μM diltiazem). At 72 h p.i., cells were lysed and total RNA was extracted. cDNA libraries were then produced, amplified, and subjected to high-throughput sequencing. Taking the mock-infected / mock-treated (“mock”) as baseline, we initially performed DAVID functional gene enrichment (absolute fold change &gt;2, Benjamini-Hochberg corrected p-value &lt;0.05) on the specific transcriptional signature of diltiazem with the objective of gaining insight on the putative host pathways involved in its antiviral effect. The lists of up-regulated (n=194) and down-regulated (n=110) transcripts in the mock-infected / diltiazem (“mock + diltiazem”) condition were analyzed using DAVID 6.8 to highlight associations with specific GO terms. Although no enriched BP was identified among down-regulated transcripts, the list of up-regulated transcripts associated with diltiazem treatment highlighted 7 particularly enriched BP. While 4 of these BP (GO:0009615; GO:0045071; GO:0051607; GO:0060337) are directly linked to antiviral response/cellular response to virus, the remaining 3 (GO:0055114; GO:0008299; GO:0006695) are involved in cholesterol biosynthesis/metabolism (<bold><xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-2" hwp:rel-id="F6">Figure 6A</xref></bold>). We then compared the common differentially expressed transcript levels between the three infection/treatment conditions. These transcriptional signatures revealed a marked anti-correlated profile between the “mock + diltiazem” and the infected / mock-treated (“H1N1”) conditions (<bold><xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-3" hwp:rel-id="F6">Figure 6B</xref></bold>), supported by a median Spearman’s ρ correlation value of -0.82 (<bold><xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-4" hwp:rel-id="F6">Figure 6C</xref></bold>). Most important, the infected / diltiazem (“H1N1 + diltiazem”) condition yielded ρ correlation values of 0.40 and -0.72 when compared to either “mock + diltiazem” or “H1N1”, respectively, therefore confirming a partial reversion of the infection virogenomic signature during effective antiviral treatment with diltiazem (<bold><xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-5" hwp:rel-id="F6">Figures 6D</xref> and S4</bold>), as expected.</p><fig id="fig6" position="float" fig-type="figure" orientation="portrait" hwp:id="F6" hwp:rev-id="xref-fig-6-1 xref-fig-6-2 xref-fig-6-3 xref-fig-6-4 xref-fig-6-5 xref-fig-6-6"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/FIG6</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F6</object-id><object-id pub-id-type="publisher-id">fig6</object-id><label>Fig. 6.</label><caption hwp:id="caption-7"><title hwp:id="title-36">Diltiazem treatment effectively induces significant reversion of the viral infection signature.</title><p hwp:id="p-43"><bold>(A)</bold> DAVID gene enrichment analysis of the diltiazem transcriptional signature. The seven most significant biological processes (BP) are presented. BP related to antiviral response and cholesterol biosynthesis/metabolism are represented in blue and green, respectively. <bold>(B)</bold> Hierarchical clustering and heatmap of the 118 common differentially expressed transcripts (absolute fold change &gt;2, Benjamini-Hochberg corrected p-value &lt;0.05) between mock-infected / diltiazem (“mock + diltiazem”), infected / mock-treated (“H1N1”), or infected / diltiazem (“H1N1 + diltiazem”) HAE. The mock-infected / mock-treated (“mock”) condition was used as baseline. Mean-weighted fold changes are color-coded from blue to yellow. <bold>(C)</bold> Median Spearman ρ correlation value calculations between the 3 conditions highlighted in the heatmap. <bold>(D)</bold> Stacked barplot representation of the 40 most up/down-regulated transcripts highlighted in the analysis. Barplots were constructed in R3.3.1 based on mean-weighted fold changes and ordered according to H1N1 values (blue). Mock + diltiazem and H1N1 + diltiazem conditions are represented in yellow and green, respectively.</p></caption><graphic xlink:href="401315_fig6" position="float" orientation="portrait" hwp:id="graphic-7"/></fig></sec></sec><sec id="s4" hwp:id="sec-28"><title hwp:id="title-37">Discussion</title><p hwp:id="p-44">The existing urge for alternative strategies to cope with the limited efficacy of currently approved antivirals for the prevention and treatment of influenza infections [<xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-2" hwp:rel-id="ref-2">2</xref>, <xref ref-type="bibr" rid="c41" hwp:id="xref-ref-41-1" hwp:rel-id="ref-41">41</xref>, <xref ref-type="bibr" rid="c42" hwp:id="xref-ref-42-1" hwp:rel-id="ref-42">42</xref>], mostly in the case of patients with severe influenza and acute respiratory distress syndrome (ARDS) [<xref ref-type="bibr" rid="c43" hwp:id="xref-ref-43-1" hwp:rel-id="ref-43">43</xref>, <xref ref-type="bibr" rid="c44" hwp:id="xref-ref-44-1" hwp:rel-id="ref-44">44</xref>], represented the central driving force of this study. Here, we developed and validated for the first time an innovative approach based on clinical genomic signatures of respiratory viral infections for the rapid discovery, <italic toggle="yes">in vitro, in vivo</italic> and <italic toggle="yes">ex-vivo</italic> evaluation, as well as the repurposing of FDA-approved drugs for their newly identified host-targeted inhibitory and protective properties against influenza infections.</p><p hwp:id="p-45">Targeting host components on which viral replication depends instead of viral determinants represents a real change of paradigm in antiviral development, with pioneering results mainly observed in the context of antiretroviral therapy [<xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-2" hwp:rel-id="ref-13">13</xref>, <xref ref-type="bibr" rid="c45" hwp:id="xref-ref-45-1" hwp:rel-id="ref-45">45</xref>]. Nevertheless, and despite strong putative advantages such as the achievement of broad-spectrum antiviral efficacy and the minimization of viral drug resistance, this approach usually fails to overcome two major limiting factors of classic compound screening. Firstly, it remains target-centered <italic toggle="yes">per se</italic>, therefore leading to the identification of drugs with limited efficacy due to the complex network and high redundancy of the host cellular pathways. Secondly, the need of high-throughput screenings often entails the measurement of a very limited number of viral parameters, usually in non-physiologically and hence poorly relevant conditions and/or cellular models.</p><p hwp:id="p-46">Based on our initial proof-of-concept study on the <italic toggle="yes">in silico</italic> screening of the CMAP database [<xref ref-type="bibr" rid="c19" hwp:id="xref-ref-19-3" hwp:rel-id="ref-19">19</xref>, <xref ref-type="bibr" rid="c20" hwp:id="xref-ref-20-3" hwp:rel-id="ref-20">20</xref>] with no initial <italic toggle="yes">a priori</italic> on specific host targets [<xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-3" hwp:rel-id="ref-18">18</xref>], we moved our approach up to the clinical trial setting, by determining exploitable and more relevant virogenomic profiles directly from standard clinical samples of influenza-infected patients. Since the low amount of often degraded RNA obtained from these samples represented a major challenge, we implemented an original combination of sample preparation techniques for low input but high quality samples with data processing initially designed for expression analysis of non-model species [<xref ref-type="bibr" rid="c22" hwp:id="xref-ref-22-2" hwp:rel-id="ref-22">22</xref>, <xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-5" hwp:rel-id="ref-23">23</xref>].</p><p hwp:id="p-47">Another substantial development was the integration of several lists of candidate molecules issued from different transcriptomic signatures with enriched relevant DAVID Gene Ontology terms, and their final selection based on their pharmacological classes and potential compatibility as antivirals. Our refined strategy allowed the selection of a shortlist of 35 high potential candidates out of a rationalized computational screening of a total of 1,309 FDA-approved bioactive molecules. This drastic positive selection step constituted a major advantage, since it enabled the implementation of relevant and integrated <italic toggle="yes">in vitro, in vivo</italic> and <italic toggle="yes">ex-vivo</italic> evaluations in a time- and cost-effective manner. Most important, the use of patient (<italic toggle="yes">in vivo)</italic> virogenomic profiles led to the identification of molecules with highly improved <italic toggle="yes">in vitro</italic> activity and significant <italic toggle="yes">in vivo</italic> antiviral efficacy as compared with compounds previously obtained from our initial study based on cell culture (<italic toggle="yes">in vitro)</italic> virogenomic profiles [<xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-4" hwp:rel-id="ref-18">18</xref>]. These results truly highlight the added value of using relevant clinical virogenomic signatures to optimize the computational screening for active drugs.</p><p hwp:id="p-48">Two of the molecules identified in this study with transcriptomic profiles that counteract clinical virogenomic signatures (e.g. ribavirin and monensin) have already been validated for their anti-influenza properties [<xref ref-type="bibr" rid="c38" hwp:id="xref-ref-38-2" hwp:rel-id="ref-38">38</xref>, <xref ref-type="bibr" rid="c40" hwp:id="xref-ref-40-2" hwp:rel-id="ref-40">40</xref>], and then supported the relevance of our compound selection strategy. Nevertheless, although different modes of action have been postulated for the anti-influenza activity of the synthetic guanosine analog ribavirin [<xref ref-type="bibr" rid="c39" hwp:id="xref-ref-39-2" hwp:rel-id="ref-39">39</xref>], the exact mechanisms remain uncharacterized so far. Similarly, it has been postulated that monensin, an antibiotic isolated from <italic toggle="yes">Streptomyces spp</italic>, may have a role as a ionophore that interferes with intracellular transport of several enveloped viruses, including influenza [<xref ref-type="bibr" rid="c40" hwp:id="xref-ref-40-3" hwp:rel-id="ref-40">40</xref>]. In that sense, even if we cannot rule out that some of the molecules identified <italic toggle="yes">in silico</italic> exert a direct effect on a specific pathway or cellular target, the fact that these molecules have been identified with a high anti-correlation rate in CMAP strongly supports a potential multi-target inhibitory effect, probably resulting in deep modifications of host gene expression. In fact, both monensin and ribavirin were previously reported to modulate the host cellular gene expression profile, notably through the up-regulation of the cholesterol and lipid biosynthesis genes [<xref ref-type="bibr" rid="c46" hwp:id="xref-ref-46-1" hwp:rel-id="ref-46">46</xref>] or the virus-induced ISRE signaling and antiviral ISGs genes [<xref ref-type="bibr" rid="c47" hwp:id="xref-ref-47-1" hwp:rel-id="ref-47">47</xref>], respectively.</p><p hwp:id="p-49">The two most promising molecules highlighted in this study are etilefrine, an alpha and beta-adrenergic receptor agonist, currently indicated as a cardiotonic and anti-hypotensive agent [<xref ref-type="bibr" rid="c48" hwp:id="xref-ref-48-1" hwp:rel-id="ref-48">48</xref>] and mainly diltiazem, a voltage-gated Ca2+ channel antagonist that is currently used to control angina pectoris and cardiac arrhythmia [<xref ref-type="bibr" rid="c49" hwp:id="xref-ref-49-1" hwp:rel-id="ref-49">49</xref>]. In addition to their strong inhibitory effect on the viral growth of circulating A(H1N1)pdm09 viruses, with <italic toggle="yes">in vitro</italic> EC50 values in the nanomolar range (<bold><xref rid="fig2" ref-type="fig" hwp:id="xref-fig-2-8" hwp:rel-id="F2">Figure 2</xref></bold>), both molecules also demonstrated antiviral properties against oseltamivir-resistant A(H1N1)pdm09 and prototype H3N2 and B influenza strains (<bold>Table S4</bold>). Our <italic toggle="yes">in vivo</italic> results (<bold><xref rid="fig3" ref-type="fig" hwp:id="xref-fig-3-4" hwp:rel-id="F3">Figures 3</xref></bold>-<bold><xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-7" hwp:rel-id="F4">4</xref></bold>), obtained without previous treatment optimization in terms of dosage or administration route, also suggest that these drugs harbor a protective role towards influenza infection, particularly in the case of diltiazem, which conferred increased survival in mice even in a model of severe influenza infection (<bold><xref rid="fig4" ref-type="fig" hwp:id="xref-fig-4-8" hwp:rel-id="F4">Figure 4D</xref></bold>-<bold>F</bold>). Moreover, the inhibitory and protective properties of diltiazem were validated in the reconstituted human airway epithelium model, also showing enhanced efficacy when combined with oseltamivir (<bold><xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-5" hwp:rel-id="F5">Figure 5</xref></bold>).</p><p hwp:id="p-50">Finally, a very recent study by Fujioka and colleagues [<xref ref-type="bibr" rid="c50" hwp:id="xref-ref-50-1" hwp:rel-id="ref-50">50</xref>] confirmed the antiviral activity of diltiazem anticipated by our approach. In that study, based on the role of Ca2+ channels on the attachment of influenza viruses to the host cell, the authors discuss whether the diltiazem induced modulation of Ca2+ channel activity might not fully explain such observed antiviral activity, consistent with a multi-level (off-target) effect of diltiazem. In this context, in which not all Ca2+ channel inhibitors confer significant antiviral activity, the newly described capacity of diltiazem to partially reverse the global virogenomic signature of infection and modulate specific genes related to the host antiviral response and cholesterol metabolism (<bold><xref rid="fig6" ref-type="fig" hwp:id="xref-fig-6-6" hwp:rel-id="F6">Figures 6</xref> and S4</bold>) suggests a putative explanation for its inhibitory effect observed <italic toggle="yes">in vitro, ex vivo</italic> and in mice. Nevertheless, further investigations are underscored to shed light on the specific mechanisms underlying such potential multi-level mode of action of diltiazem.</p></sec><sec id="s5" hwp:id="sec-29"><title hwp:id="title-38">Conclusions</title><p hwp:id="p-51">Overall, the results presented here set a solid baseline for our drug repurposing strategy and for the use of diltiazem as a host-targeted antiviral in clinical practice. Moreover, the increased antiviral efficacy observed in reconstituted human airway epithelium (<bold><xref rid="fig5" ref-type="fig" hwp:id="xref-fig-5-6" hwp:rel-id="F5">Figures 5B</xref></bold> and <bold>S6 Table</bold>) plead in favor of the combination of diltiazem with the virus-targeted antiviral oseltamivir for the improvement of current anti-influenza therapy, and possibly decreasing the risk of development of viral resistance. In that regard, our results prompted a French multicenter randomized clinical trial aimed at assessing the effect of diltiazem-oseltamivir bitherapy compared with standard oseltamivir monotherapy for the treatment of severe influenza infections in intensive care units, hence completing the bedside-to-bench and bench-to-bedside cycle of our innovative approach. Additionally, retrospective signature analysis of sequential respiratory samples from patients included in both study arms and stratified according to their clinical response to treatment will provide valuable data to pursue the investigations on the specific mediators of the diltiazem-related antiviral response. This trial (FLUNEXT TRIAL PHRC #15-0442, ClinicalTrials.gov identifier <ext-link l:rel="related" l:ref-type="CLINTRIALGOV" l:ref="NCT03212716" ext-link-type="clintrialgov" xlink:href="NCT03212716" hwp:id="ext-link-5">NCT03212716</ext-link>) is currently ongoing.</p><p hwp:id="p-52">Finally, our study underscores the high value of clinical specimens and the advantages of exploiting virogenomic and chemogenomic data for the successful systematic repurposing of drugs already available in our modern pharmacopeia as new effective antivirals. We propose that our approach targeting respiratory epithelial cells, the principal influenza infected cell type in the lung, could be extended to other respiratory viruses and eventually to other pathogens involved in acute infections. Importantly, drug repurposing presents several financial and regulatory advantages compared to the development of <italic toggle="yes">de novo</italic> molecules [<xref ref-type="bibr" rid="c5" hwp:id="xref-ref-5-2" hwp:rel-id="ref-5">5</xref>], which are of particular interest not only in the context of antimicrobial resistance but also against both emerging or recurrent pathogens for which we are still disarmed.</p></sec></body><back><sec id="s6" hwp:id="sec-30"><title hwp:id="title-39">Declarations</title><sec id="s6a" hwp:id="sec-31"><title hwp:id="title-40">Ethics approval and consent to participate</title><p hwp:id="p-53">Adult patients were recruited by general practitioners in the context of a previously published randomized clinical trial (Escuret et al., 2012) (ClinicalTrials.gov identifier <ext-link l:rel="related" l:ref-type="CLINTRIALGOV" l:ref="NCT00830323" ext-link-type="clintrialgov" xlink:href="NCT00830323" hwp:id="ext-link-6">NCT00830323</ext-link>) and all of them provided written informed consent. The study protocol was approved by the Lyon Ethics Committee (Comité de Protection des Personnes Lyon B) on September 9th, 2009 and conducted in accordance with the Declaration of Helsinki.</p><p hwp:id="p-54">All animal procedures were approved by the Institutional Animal Care Committee of the Centre Hospitalier Universitaire de Québec (CPAC protocol authorization #2012-068-3) according to the guidelines of the Canadian Council on Animal Care.</p></sec><sec id="s6b" hwp:id="sec-32"><title hwp:id="title-41">Consent for publication</title><p hwp:id="p-55">Not applicable.</p></sec><sec id="s6c" hwp:id="sec-33"><title hwp:id="title-42">Availability of data and material</title><p hwp:id="p-56">The main datasets supporting the conclusions of this article are included within the article and its additional files. All raw microarray data from virogenomic signatures were deposited on the National Center for Biotechnology Information’s Gene Expression Omnibus (GEO), under accession number GSE93731. Other datasets used and/or analyzed during the current study are available from the corresponding authors on reasonable request.</p></sec><sec id="s6d" hwp:id="sec-34"><title hwp:id="title-43">Competing interests</title><p hwp:id="p-57">AP, OT, JT, GB and MRC are co-inventors of a patent application filed by INSERM, Université Claude Bernard Lyon 1, Laval University and Hospices Civils de Lyon for the repurposing of diltiazem and etilefrine as anti-influenza agents (FR15/52284 - PCT/ep2016/056036 - WO2016146836). The authors have no additional financial interests.</p></sec><sec id="s6e" hwp:id="sec-35"><title hwp:id="title-44">Funding</title><p hwp:id="p-58">This work was funded by grants from the French Ministry of Social Affairs and Health (DGOS), Institut National de la Santé et de la Recherche Médicale (INSERM), the Université Claude Bernard Lyon 1, the Région Auvergne Rhône-Alpes (CMIRA N° 14007029 and AccueilPro COOPERA N°15458 grants), and Canadian Institutes of Health Research (N° 229733 and 230187). Guy Boivin is the holder of the Canada Research Chair on influenza and other respiratory viruses. Funding institutions had no participation in the design of the study, collection, analysis and interpretation of data, or in the writing of the manuscript.</p></sec><sec id="s6f" hwp:id="sec-36"><title hwp:id="title-45">Authors’ contributions</title><p hwp:id="p-59">AP, OT, JT, GB and MRC designed and coordinated the study. VE, JP and BL acquired clinical data from the cohort. AP, OT, TJ, BP, AT, MR, MEH, CR, CNL, SC, CLL and JT performed experiments and provided technical support. AP, OT, MR, JP, JT, GB and MRC interpreted data. AP, OT and MRC wrote the manuscript. JT, GB and MRC revised the manuscript.</p></sec></sec><ack hwp:id="ack-1"><title hwp:id="title-46">Acknowledgements:</title><p hwp:id="p-60">The authors want to thank Jacques Corbeil and Frederic Raymond (Research Center in Infectious Diseases of the CHU de Quebec and Laval University, Quebec) for their help and useful advice.</p></ack><ref-list hwp:id="ref-list-1"><title hwp:id="title-47">References</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1"><label>1.</label><citation publication-type="other" citation-type="journal" ref:id="401315v1.1" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-1"><collab hwp:id="collab-1">Influenza facts Sheet n°211</collab>. <year>2014</year>. <ext-link l:rel="related" l:ref-type="uri" l:ref="http://www.who.int/mediacentre/factsheets/fs211/en/" ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs211/en/" hwp:id="ext-link-7">http://www.who.int/mediacentre/factsheets/fs211/en/</ext-link>. <date-in-citation>Accessed 20 Jan 2016</date-in-citation>.</citation></ref><ref id="c2" hwp:id="ref-2" hwp:rev-id="xref-ref-2-1 xref-ref-2-2"><label>2.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><string-name name-style="western" hwp:sortable="Loregian A"><surname>Loregian</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mercorelli B"><surname>Mercorelli</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nannetti G"><surname>Nannetti</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Compagnin C"><surname>Compagnin</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Palù G."><surname>Palù</surname> <given-names>G.</given-names></string-name> <article-title hwp:id="article-title-2">ntiviral strategies against influenza virus: towards new therapeutic approaches</article-title>. <source hwp:id="source-1">Cell Mol Life Sci CMLS</source>. <year>2014</year>;<volume>71</volume>:<fpage>3659</fpage>–<lpage>83</lpage>.</citation></ref><ref id="c3" hwp:id="ref-3" hwp:rev-id="xref-ref-3-1 xref-ref-3-2"><label>3.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Booth B"><surname>Booth</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zemmel R."><surname>Zemmel</surname> <given-names>R.</given-names></string-name> <article-title hwp:id="article-title-3">Prospects for productivity</article-title>. <source hwp:id="source-2">Nat Rev Drug Discov</source>. <year>2004</year>;<volume>3</volume>:<fpage>451</fpage>–<lpage>6</lpage>.</citation></ref><ref id="c4" hwp:id="ref-4"><label>4.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Ashburn TT"><surname>Ashburn</surname> <given-names>TT</given-names></string-name>, <string-name name-style="western" hwp:sortable="Thor KB"><surname>Thor</surname> <given-names>KB</given-names></string-name>. <article-title hwp:id="article-title-4">Drug repositioning: identifying and developing new uses for existing drugs</article-title>. <source hwp:id="source-3">Nat Rev Drug Discov</source>. <year>2004</year>;<volume>3</volume>:<fpage>673</fpage>–<lpage>83</lpage>.</citation></ref><ref id="c5" hwp:id="ref-5" hwp:rev-id="xref-ref-5-1 xref-ref-5-2"><label>5.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.5" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Law GL"><surname>Law</surname> <given-names>GL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tisoncik-Go J"><surname>Tisoncik-Go</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Korth MJ"><surname>Korth</surname> <given-names>MJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Katze MG"><surname>Katze</surname> <given-names>MG</given-names></string-name>. <article-title hwp:id="article-title-5">Drug repurposing: a better approach for infectious disease drug discovery?</article-title> <source hwp:id="source-4">Curr Opin Immunol</source>. <year>2013</year>;<volume>25</volume>:<fpage>588</fpage>–<lpage>92</lpage>.</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1"><label>6.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Johansen LM"><surname>Johansen</surname> <given-names>LM</given-names></string-name>, <string-name name-style="western" hwp:sortable="DeWald LE"><surname>DeWald</surname> <given-names>LE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Shoemaker CJ"><surname>Shoemaker</surname> <given-names>CJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hoffstrom BG"><surname>Hoffstrom</surname> <given-names>BG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lear-Rooney CM"><surname>Lear-Rooney</surname> <given-names>CM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stossel A"><surname>Stossel</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-6">A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity</article-title>. <source hwp:id="source-5">Sci Transl Med</source>. <year>2015</year>;<volume>7</volume>:<fpage>290ra89</fpage>.</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1"><label>7.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.7" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Xu M"><surname>Xu</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lee EM"><surname>Lee</surname> <given-names>EM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wen Z"><surname>Wen</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cheng Y"><surname>Cheng</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Huang W-K"><surname>Huang</surname> <given-names>W-K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Qian X"><surname>Qian</surname> <given-names>X</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-7">Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</article-title>. <source hwp:id="source-6">Nat Med</source>. <year>2016</year>;<volume>22</volume>:<fpage>1101</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c8" hwp:id="ref-8" hwp:rev-id="xref-ref-8-1"><label>8.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.8" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Naylor S"><surname>Naylor</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schonfeld JM"><surname>Schonfeld</surname> <given-names>JM</given-names></string-name>. <article-title hwp:id="article-title-8">Therapeutic drug repurposing, repositioning and rescue - Part I: Overview</article-title>. <source hwp:id="source-7">Drug Discov World</source>. <year>2014</year>;<volume>16</volume>. <ext-link l:rel="related" l:ref-type="uri" l:ref="https://www.researchgate.net/publication/286670692_Therapeutic_drug_repurposing_repositioning_and_rescue_-_Part_I_Overview" ext-link-type="uri" xlink:href="https://www.researchgate.net/publication/286670692_Therapeutic_drug_repurposing_repositioning_and_rescue_-_Part_I_Overview" hwp:id="ext-link-8">https://www.researchgate.net/publication/286670692_Therapeutic_drug_repurposing_repositioning_and_rescue_-_Part_I_Overview</ext-link>. <date-in-citation>Accessed 11 Jan 2017</date-in-citation>.</citation></ref><ref id="c9" hwp:id="ref-9" hwp:rev-id="xref-ref-9-1"><label>9.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.9" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Keiser MJ"><surname>Keiser</surname> <given-names>MJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Setola V"><surname>Setola</surname> <given-names>V</given-names></string-name>, <string-name name-style="western" hwp:sortable="Irwin JJ"><surname>Irwin</surname> <given-names>JJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Laggner C"><surname>Laggner</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Abbas AI"><surname>Abbas</surname> <given-names>AI</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hufeisen SJ"><surname>Hufeisen</surname> <given-names>SJ</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-9">Predicting new molecular targets for known drugs</article-title>. <source hwp:id="source-8">Nature</source>. <year>2009</year>;<volume>462</volume>:<fpage>175</fpage>–<lpage>81</lpage>.</citation></ref><ref id="c10" hwp:id="ref-10" hwp:rev-id="xref-ref-10-1"><label>10.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.10" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Haupt VJ"><surname>Haupt</surname> <given-names>VJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schroeder M."><surname>Schroeder</surname> <given-names>M.</given-names></string-name> <article-title hwp:id="article-title-10">Old friends in new guise: repositioning of known drugs with structural bioinformatics</article-title>. <source hwp:id="source-9">Brief Bioinform</source>. <year>2011</year>;<volume>12</volume>:<fpage>312</fpage>–<lpage>26</lpage>.</citation></ref><ref id="c11" hwp:id="ref-11" hwp:rev-id="xref-ref-11-1"><label>11.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Li Y"><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Agarwal P."><surname>Agarwal</surname> <given-names>P.</given-names></string-name> <article-title hwp:id="article-title-11">A pathway-based view of human diseases and disease relationships</article-title>. <source hwp:id="source-10">PloS One</source>. <year>2009</year>;<volume>4</volume>:<fpage>e4346</fpage>.</citation></ref><ref id="c12" hwp:id="ref-12" hwp:rev-id="xref-ref-12-1"><label>12.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="Lussier YA"><surname>Lussier</surname> <given-names>YA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chen JL"><surname>Chen</surname> <given-names>JL</given-names></string-name>. <article-title hwp:id="article-title-12">The emergence of genome-based drug repositioning</article-title>. <source hwp:id="source-11">Sci Transl Med</source>. <year>2011</year>;<volume>3</volume>:<fpage>96ps35</fpage>.</citation></ref><ref id="c13" hwp:id="ref-13" hwp:rev-id="xref-ref-13-1 xref-ref-13-2"><label>13.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Hütter G"><surname>Hütter</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bodor J"><surname>Bodor</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ledger S"><surname>Ledger</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Boyd M"><surname>Boyd</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Millington M"><surname>Millington</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tsie M"><surname>Tsie</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-13">CCR5 Targeted Cell Therapy for HIV and Prevention of Viral Escape</article-title>. <source hwp:id="source-12">Viruses</source>. <year>2015</year>;<volume>7</volume>:<fpage>4186</fpage>–<lpage>203</lpage>.</citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1"><label>14.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Ludwig S."><surname>Ludwig</surname> <given-names>S.</given-names></string-name> <article-title hwp:id="article-title-14">Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections</article-title>. <source hwp:id="source-13">Biol Chem</source>. <year>2011</year>;<volume>392</volume>:<fpage>837</fpage>–<lpage>47</lpage>.</citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1"><label>15.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Rossignol JF"><surname>Rossignol</surname> <given-names>JF</given-names></string-name>, <string-name name-style="western" hwp:sortable="La Frazia S"><surname>La Frazia</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chiappa L"><surname>Chiappa</surname> <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ciucci A"><surname>Ciucci</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Santoro MG"><surname>Santoro</surname> <given-names>MG</given-names></string-name>. <article-title hwp:id="article-title-15">Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level</article-title>. <source hwp:id="source-14">J Biol Chem</source>. <year>2009</year>;<volume>284</volume>:<fpage>29798</fpage>–<lpage>808</lpage>.</citation></ref><ref id="c16" hwp:id="ref-16"><label>16.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.16" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Belser JA"><surname>Belser</surname> <given-names>JA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lu X"><surname>Lu</surname> <given-names>X</given-names></string-name>, <string-name name-style="western" hwp:sortable="Szretter KJ"><surname>Szretter</surname> <given-names>KJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jin X"><surname>Jin</surname> <given-names>X</given-names></string-name>, <string-name name-style="western" hwp:sortable="Aschenbrenner LM"><surname>Aschenbrenner</surname> <given-names>LM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lee A"><surname>Lee</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-16">DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection</article-title>. <source hwp:id="source-15">J Infect Dis</source>. <year>2007</year>;<volume>196</volume>:<fpage>1493</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c17" hwp:id="ref-17" hwp:rev-id="xref-ref-17-1"><label>17.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.17" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="Mazur I"><surname>Mazur</surname> <given-names>I</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wurzer WJ"><surname>Wurzer</surname> <given-names>WJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ehrhardt C"><surname>Ehrhardt</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pleschka S"><surname>Pleschka</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Puthavathana P"><surname>Puthavathana</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Silberzahn T"><surname>Silberzahn</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-17">Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity</article-title>. <source hwp:id="source-16">Cell Microbiol</source>. <year>2007</year>;<volume>9</volume>:<fpage>1683</fpage>–<lpage>94</lpage>.</citation></ref><ref id="c18" hwp:id="ref-18" hwp:rev-id="xref-ref-18-1 xref-ref-18-2 xref-ref-18-3 xref-ref-18-4"><label>18.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.18" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-18"><string-name name-style="western" hwp:sortable="Josset L"><surname>Josset</surname> <given-names>L</given-names></string-name>, <string-name name-style="western" hwp:sortable="Textoris J"><surname>Textoris</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Loriod B"><surname>Loriod</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ferraris O"><surname>Ferraris</surname> <given-names>O</given-names></string-name>, <string-name name-style="western" hwp:sortable="Moules V"><surname>Moules</surname> <given-names>V</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lina B"><surname>Lina</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-18">Gene expression signature-based screening identifies new broadly effective influenza a antivirals</article-title>. <source hwp:id="source-17">PloS One</source>. <year>2010</year>;<volume>5</volume>.</citation></ref><ref id="c19" hwp:id="ref-19" hwp:rev-id="xref-ref-19-1 xref-ref-19-2 xref-ref-19-3"><label>19.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.19" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-19"><string-name name-style="western" hwp:sortable="Lamb J"><surname>Lamb</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Crawford ED"><surname>Crawford</surname> <given-names>ED</given-names></string-name>, <string-name name-style="western" hwp:sortable="Peck D"><surname>Peck</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Modell JW"><surname>Modell</surname> <given-names>JW</given-names></string-name>, <string-name name-style="western" hwp:sortable="Blat IC"><surname>Blat</surname> <given-names>IC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wrobel MJ"><surname>Wrobel</surname> <given-names>MJ</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-19">The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease</article-title>. <source hwp:id="source-18">Science</source>. <year>2006</year>;<volume>313</volume>:<fpage>1929</fpage>–<lpage>35</lpage>.</citation></ref><ref id="c20" hwp:id="ref-20" hwp:rev-id="xref-ref-20-1 xref-ref-20-2 xref-ref-20-3"><label>20.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.20" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-20"><string-name name-style="western" hwp:sortable="Lamb J."><surname>Lamb</surname> <given-names>J.</given-names></string-name> <article-title hwp:id="article-title-20">The Connectivity Map: a new tool for biomedical research</article-title>. <source hwp:id="source-19">Nat Rev Cancer</source>. <year>2007</year>;<volume>7</volume>:<fpage>54</fpage>–<lpage>60</lpage>.</citation></ref><ref id="c21" hwp:id="ref-21" hwp:rev-id="xref-ref-21-1 xref-ref-21-2"><label>21.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.21" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-21"><string-name name-style="western" hwp:sortable="Escuret V"><surname>Escuret</surname> <given-names>V</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cornu C"><surname>Cornu</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Boutitie F"><surname>Boutitie</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Enouf V"><surname>Enouf</surname> <given-names>V</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mosnier A"><surname>Mosnier</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bouscambert-Duchamp M"><surname>Bouscambert-Duchamp</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-21">Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections</article-title>. <source hwp:id="source-20">Antiviral Res</source>. <year>2012</year>;<volume>96</volume>:<fpage>130</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c22" hwp:id="ref-22" hwp:rev-id="xref-ref-22-1 xref-ref-22-2"><label>22.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.22" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-22"><string-name name-style="western" hwp:sortable="Khaznadar Z"><surname>Khaznadar</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Boissel N"><surname>Boissel</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Agaugué S"><surname>Agaugué</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Henry G"><surname>Henry</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cheok M"><surname>Cheok</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Vignon M"><surname>Vignon</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-22">Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion</article-title>. <source hwp:id="source-21">J Immunol Baltim Md 1950</source>. <year>2015</year>;<volume>195</volume>:<fpage>2580</fpage>–<lpage>90</lpage>.</citation></ref><ref id="c23" hwp:id="ref-23" hwp:rev-id="xref-ref-23-1 xref-ref-23-2 xref-ref-23-3 xref-ref-23-4 xref-ref-23-5"><label>23.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.23" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-23"><string-name name-style="western" hwp:sortable="Degletagne C"><surname>Degletagne</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Keime C"><surname>Keime</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rey B"><surname>Rey</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="de Dinechin M"><surname>de Dinechin</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Forcheron F"><surname>Forcheron</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chuchana P"><surname>Chuchana</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-23">Transcriptome analysis in non-model species: a new method for the analysis of heterologous hybridization on microarrays</article-title>. <source hwp:id="source-22">BMC Genomics</source>. <year>2010</year>;<volume>11</volume>:<fpage>344</fpage>.</citation></ref><ref id="c24" hwp:id="ref-24" hwp:rev-id="xref-ref-24-1"><label>24.</label><citation publication-type="book" citation-type="book" ref:id="401315v1.24" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-24"><string-name name-style="western" hwp:sortable="Tukey J"><surname>Tukey</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wilder J."><surname>Wilder</surname> <given-names>J.</given-names></string-name> <source hwp:id="source-23">Exploratory Data Analysis</source>. <publisher-name>Addison-Wesley</publisher-name>; <year>1977</year>.</citation></ref><ref id="c25" hwp:id="ref-25" hwp:rev-id="xref-ref-25-1"><label>25.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.25" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-25"><string-name name-style="western" hwp:sortable="Benjamini Y"><surname>Benjamini</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hochberg Y."><surname>Hochberg</surname> <given-names>Y.</given-names></string-name> <article-title hwp:id="article-title-24">Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing</article-title>. <source hwp:id="source-24">J R Stat Soc Ser B Methodol</source>. <year>1995</year>;<volume>57</volume>:<fpage>289</fpage>–<lpage>300</lpage>.</citation></ref><ref id="c26" hwp:id="ref-26" hwp:rev-id="xref-ref-26-1"><label>26.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.26" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-26"><string-name name-style="western" hwp:sortable="Barrett T"><surname>Barrett</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Edgar R."><surname>Edgar</surname> <given-names>R.</given-names></string-name> <article-title hwp:id="article-title-25">Gene expression omnibus: microarray data storage, submission, retrieval, and analysis</article-title>. <source hwp:id="source-25">Methods Enzymol</source>. <year>2006</year>;<volume>411</volume>:<fpage>352</fpage>–<lpage>69</lpage>.</citation></ref><ref id="c27" hwp:id="ref-27" hwp:rev-id="xref-ref-27-1 xref-ref-27-2"><label>27.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.27" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-27"><string-name name-style="western" hwp:sortable="Dennis G Jr"><surname>Dennis G</surname> <given-names>Jr</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sherman BT"><surname>Sherman</surname> <given-names>BT</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hosack DA"><surname>Hosack</surname> <given-names>DA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yang J"><surname>Yang</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Gao W"><surname>Gao</surname> <given-names>W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lane HC"><surname>Lane</surname> <given-names>HC</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-26">DAVID: Database for Annotation, Visualization, and Integrated Discovery</article-title>. <source hwp:id="source-26">Genome Biol</source>. <year>2003</year>;<volume>4</volume>:<fpage>P3</fpage>.</citation></ref><ref id="c28" hwp:id="ref-28" hwp:rev-id="xref-ref-28-1"><label>28.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.28" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-28"><string-name name-style="western" hwp:sortable="Ashburner M"><surname>Ashburner</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ball CA"><surname>Ball</surname> <given-names>CA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Blake JA"><surname>Blake</surname> <given-names>JA</given-names></string-name>, <string-name name-style="western" hwp:sortable="Botstein D"><surname>Botstein</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Butler H"><surname>Butler</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Cherry JM"><surname>Cherry</surname> <given-names>JM</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-27">Gene ontology: tool for the unification of biology</article-title>. <source hwp:id="source-27">The Gene Ontology Consortium. Nat Genet</source>. <year>2000</year>;<volume>25</volume>:<fpage>25</fpage>–<lpage>9</lpage>.</citation></ref><ref id="c29" hwp:id="ref-29" hwp:rev-id="xref-ref-29-1 xref-ref-29-2"><label>29.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.29" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-29"><string-name name-style="western" hwp:sortable="Hatakeyama S"><surname>Hatakeyama</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sakai-Tagawa Y"><surname>Sakai-Tagawa</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kiso M"><surname>Kiso</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Goto H"><surname>Goto</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kawakami C"><surname>Kawakami</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mitamura K"><surname>Mitamura</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-28">Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor</article-title>. <source hwp:id="source-28">J Clin Microbiol</source>. <year>2005</year>;<volume>43</volume>:<fpage>4139</fpage>–<lpage>46</lpage>.</citation></ref><ref id="c30" hwp:id="ref-30" hwp:rev-id="xref-ref-30-1"><label>30.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.30" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-30"><string-name name-style="western" hwp:sortable="Moules V"><surname>Moules</surname> <given-names>V</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ferraris O"><surname>Ferraris</surname> <given-names>O</given-names></string-name>, <string-name name-style="western" hwp:sortable="Terrier O"><surname>Terrier</surname> <given-names>O</given-names></string-name>, <string-name name-style="western" hwp:sortable="Giudice E"><surname>Giudice</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yver M"><surname>Yver</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rolland JP"><surname>Rolland</surname> <given-names>JP</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-29">In vitro characterization of naturally occurring influenza H3NA-viruses lacking the NA gene segment: toward a new mechanism of viral resistance?</article-title> <source hwp:id="source-29">Virology</source>. <year>2010</year>;<volume>404</volume>:<fpage>215</fpage>–<lpage>24</lpage>.</citation></ref><ref id="c31" hwp:id="ref-31" hwp:rev-id="xref-ref-31-1"><label>31.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.31" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-31"><string-name name-style="western" hwp:sortable="Tsai AW"><surname>Tsai</surname> <given-names>AW</given-names></string-name>, <string-name name-style="western" hwp:sortable="McNeil CF"><surname>McNeil</surname> <given-names>CF</given-names></string-name>, <string-name name-style="western" hwp:sortable="Leeman JR"><surname>Leeman</surname> <given-names>JR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bennett HB"><surname>Bennett</surname> <given-names>HB</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nti-Addae K"><surname>Nti-Addae</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Huang C"><surname>Huang</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-30">Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors</article-title>. <source hwp:id="source-30">Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>59</volume>:<fpage>6007</fpage>–<lpage>16</lpage>.</citation></ref><ref id="c32" hwp:id="ref-32" hwp:rev-id="xref-ref-32-1"><label>32.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.32" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-32"><string-name name-style="western" hwp:sortable="Bolger AM"><surname>Bolger</surname> <given-names>AM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lohse M"><surname>Lohse</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Usadel B."><surname>Usadel</surname> <given-names>B.</given-names></string-name> <article-title hwp:id="article-title-31">Trimmomatic: a flexible trimmer for Illumina sequence data</article-title>. <source hwp:id="source-31">Bioinforma Oxf Engl</source>. <year>2014</year>;<volume>30</volume>:<fpage>2114</fpage>–<lpage>20</lpage>.</citation></ref><ref id="c33" hwp:id="ref-33" hwp:rev-id="xref-ref-33-1"><label>33.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.33" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-33"><string-name name-style="western" hwp:sortable="Bray NL"><surname>Bray</surname> <given-names>NL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pimentel H"><surname>Pimentel</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Melsted P"><surname>Melsted</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Pachter L."><surname>Pachter</surname> <given-names>L.</given-names></string-name> <article-title hwp:id="article-title-32">Near-optimal probabilistic RNA-seq quantification</article-title>. <source hwp:id="source-32">Nat Biotechnol</source>. <year>2016</year>;<volume>34</volume>:<fpage>525</fpage>–<lpage>7</lpage>.</citation></ref><ref id="c34" hwp:id="ref-34" hwp:rev-id="xref-ref-34-1"><label>34.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.34" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-34"><string-name name-style="western" hwp:sortable="Robinson MD"><surname>Robinson</surname> <given-names>MD</given-names></string-name>, <string-name name-style="western" hwp:sortable="McCarthy DJ"><surname>McCarthy</surname> <given-names>DJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Smyth GK"><surname>Smyth</surname> <given-names>GK</given-names></string-name>. <article-title hwp:id="article-title-33">edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title>. <source hwp:id="source-33">Bioinforma Oxf Engl</source>. <year>2010</year>;<volume>26</volume>:<fpage>139</fpage>–<lpage>40</lpage>.</citation></ref><ref id="c35" hwp:id="ref-35" hwp:rev-id="xref-ref-35-1"><label>35.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.35" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-35"><string-name name-style="western" hwp:sortable="Dupinay T"><surname>Dupinay</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nguyen A"><surname>Nguyen</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Croze S"><surname>Croze</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Barbet F"><surname>Barbet</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rey C"><surname>Rey</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mavingui P"><surname>Mavingui</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-34">Next-generation sequencing of ultra-low copy samples: From clinical FFPE samples to single-cell sequencing</article-title>. <source hwp:id="source-34">Curr Top Virol</source>. <year>2013</year>;<volume>10</volume>:<fpage>63</fpage>–<lpage>83</lpage>.</citation></ref><ref id="c36" hwp:id="ref-36" hwp:rev-id="xref-ref-36-1"><label>36.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.36" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-36"><string-name name-style="western" hwp:sortable="Kinsella RJ"><surname>Kinsella</surname> <given-names>RJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kähäri A"><surname>Kähäri</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Haider S"><surname>Haider</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zamora J"><surname>Zamora</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Proctor G"><surname>Proctor</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Spudich G"><surname>Spudich</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-35">Ensembl BioMarts: a hub for data retrieval across taxonomic space</article-title>. <source hwp:id="source-35">Database J Biol Databases Curation</source>. <year>2011</year>;<volume>2011</volume>:<fpage>bar030</fpage>.</citation></ref><ref id="c37" hwp:id="ref-37" hwp:rev-id="xref-ref-37-1"><label>37.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.37" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-37"><string-name name-style="western" hwp:sortable="Flicek P"><surname>Flicek</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Amode MR"><surname>Amode</surname> <given-names>MR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Barrell D"><surname>Barrell</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Beal K"><surname>Beal</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Billis K"><surname>Billis</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Brent S"><surname>Brent</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-36">Ensembl 2014</article-title>. <source hwp:id="source-36">Nucleic Acids Res</source>. <year>2014</year>;<volume>42</volume> <issue>Database issue</issue>:<fpage>D749</fpage>–<lpage>755</lpage>.</citation></ref><ref id="c38" hwp:id="ref-38" hwp:rev-id="xref-ref-38-1 xref-ref-38-2"><label>38.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.38" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-38"><string-name name-style="western" hwp:sortable="Durr FE"><surname>Durr</surname> <given-names>FE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lindh HF"><surname>Lindh</surname> <given-names>HF</given-names></string-name>. <article-title hwp:id="article-title-37">Efficacy of ribavirin against influenza virus in tissue culture and in mice</article-title>. <source hwp:id="source-37">Ann N Y Acad Sci</source>. <year>1975</year>;<volume>255</volume>:<fpage>366</fpage>–<lpage>71</lpage>.</citation></ref><ref id="c39" hwp:id="ref-39" hwp:rev-id="xref-ref-39-1 xref-ref-39-2"><label>39.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.39" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-39"><string-name name-style="western" hwp:sortable="Leyssen P"><surname>Leyssen</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="De Clercq E"><surname>De Clercq</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Neyts J."><surname>Neyts</surname> <given-names>J.</given-names></string-name> <article-title hwp:id="article-title-38">Molecular strategies to inhibit the replication of RNA viruses</article-title>. <source hwp:id="source-38">Antiviral Res</source>. <year>2008</year>;<volume>78</volume>:<fpage>9</fpage>–<lpage>25</lpage>.</citation></ref><ref id="c40" hwp:id="ref-40" hwp:rev-id="xref-ref-40-1 xref-ref-40-2 xref-ref-40-3"><label>40.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.40" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-40"><string-name name-style="western" hwp:sortable="Alonso FV"><surname>Alonso</surname> <given-names>FV</given-names></string-name>, <string-name name-style="western" hwp:sortable="Compans RW"><surname>Compans</surname> <given-names>RW</given-names></string-name>. <article-title hwp:id="article-title-39">Differential effect of monensin on enveloped viruses that form at distinct plasma membrane domains</article-title>. <source hwp:id="source-39">J Cell Biol</source>. <year>1981</year>;<volume>89</volume>:<fpage>700</fpage>–<lpage>5</lpage>.</citation></ref><ref id="c41" hwp:id="ref-41" hwp:rev-id="xref-ref-41-1"><label>41.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.41" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-41"><string-name name-style="western" hwp:sortable="Hayden F."><surname>Hayden</surname> <given-names>F.</given-names></string-name> <article-title hwp:id="article-title-40">Developing new antiviral agents for influenza treatment: what does the future hold?</article-title> <source hwp:id="source-40">Clin Infect Dis Off Publ Infect Dis Soc Am</source>. <year>2009</year>;<volume>48</volume> Suppl <issue>1</issue>:<fpage>S3</fpage>–<lpage>13</lpage>.</citation></ref><ref id="c42" hwp:id="ref-42" hwp:rev-id="xref-ref-42-1"><label>42.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.42" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-42"><string-name name-style="western" hwp:sortable="Lee SM-Y"><surname>Lee</surname> <given-names>SM-Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yen H-L."><surname>Yen</surname> <given-names>H-L.</given-names></string-name> <article-title hwp:id="article-title-41">Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection</article-title>. <source hwp:id="source-41">Antiviral Res</source>. <year>2012</year>;<volume>96</volume>:<fpage>391</fpage>–<lpage>404</lpage>.</citation></ref><ref id="c43" hwp:id="ref-43" hwp:rev-id="xref-ref-43-1"><label>43.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.43" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-43"><string-name name-style="western" hwp:sortable="Koh Y."><surname>Koh</surname> <given-names>Y.</given-names></string-name> <article-title hwp:id="article-title-42">Update in acute respiratory distress syndrome</article-title>. <source hwp:id="source-42">J Intensive Care</source>. <year>2014</year>;<volume>2</volume>:<fpage>2</fpage>.</citation></ref><ref id="c44" hwp:id="ref-44" hwp:rev-id="xref-ref-44-1"><label>44.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.44" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-44"><string-name name-style="western" hwp:sortable="Poissy J"><surname>Poissy</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Terrier O"><surname>Terrier</surname> <given-names>O</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lina B"><surname>Lina</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Textoris J"><surname>Textoris</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rosa-Calatrava M."><surname>Rosa-Calatrava</surname> <given-names>M.</given-names></string-name> <article-title hwp:id="article-title-43">La modulation de la signature transcriptomique de l’hôte infecté?: une nouvelle stratégie thérapeutique dans les viroses graves?? Exemple de la grippe</article-title>. <source hwp:id="source-43">Réanimation</source>. <year>2016</year>;<volume>25</volume>:<fpage>53</fpage>–<lpage>61</lpage>.</citation></ref><ref id="c45" hwp:id="ref-45" hwp:rev-id="xref-ref-45-1"><label>45.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.45" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-45"><string-name name-style="western" hwp:sortable="Lou Z"><surname>Lou</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sun Y"><surname>Sun</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rao Z."><surname>Rao</surname> <given-names>Z.</given-names></string-name> <article-title hwp:id="article-title-44">Current progress in antiviral strategies</article-title>. <source hwp:id="source-44">Trends Pharmacol Sci</source>. <year>2014</year>;<volume>35</volume>:<fpage>86</fpage>–<lpage>102</lpage>.</citation></ref><ref id="c46" hwp:id="ref-46" hwp:rev-id="xref-ref-46-1"><label>46.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.46" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-46"><string-name name-style="western" hwp:sortable="Dayekh K"><surname>Dayekh</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Johnson-Obaseki S"><surname>Johnson-Obaseki</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Corsten M"><surname>Corsten</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Villeneuve PJ"><surname>Villeneuve</surname> <given-names>PJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sekhon HS"><surname>Sekhon</surname> <given-names>HS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Weberpals JI"><surname>Weberpals</surname> <given-names>JI</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-45">Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors</article-title>. <source hwp:id="source-45">Mol Cancer Ther</source>. <year>2014</year>;<volume>13</volume>:<fpage>2559</fpage>–<lpage>71</lpage>.</citation></ref><ref id="c47" hwp:id="ref-47" hwp:rev-id="xref-ref-47-1"><label>47.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.47" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-47"><string-name name-style="western" hwp:sortable="Zhang Y"><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jamaluddin M"><surname>Jamaluddin</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wang S"><surname>Wang</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Tian B"><surname>Tian</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Garofalo RP"><surname>Garofalo</surname> <given-names>RP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Casola A"><surname>Casola</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-46">Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells</article-title>. <source hwp:id="source-46">J Virol</source>. <year>2003</year>;<volume>77</volume>:<fpage>5933</fpage>–<lpage>47</lpage>.</citation></ref><ref id="c48" hwp:id="ref-48" hwp:rev-id="xref-ref-48-1"><label>48.</label><citation publication-type="other" citation-type="journal" ref:id="401315v1.48" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-48"><collab hwp:id="collab-2">Pubchem C10H15NO2</collab>. <source hwp:id="source-47">Etilefrine | C10H15NO2 - PubChem</source>. <ext-link l:rel="related" l:ref-type="uri" l:ref="https://pubchem.ncbi.nlm.nih.gov/compound/Etilefrine" ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Etilefrine" hwp:id="ext-link-9">https://pubchem.ncbi.nlm.nih.gov/compound/Etilefrine</ext-link>. <date-in-citation>Accessed 3 Feb 2017</date-in-citation>.</citation></ref><ref id="c49" hwp:id="ref-49" hwp:rev-id="xref-ref-49-1"><label>49.</label><citation publication-type="other" citation-type="journal" ref:id="401315v1.49" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-49"><collab hwp:id="collab-3">Pubchem C22H26N2O4S</collab>. <source hwp:id="source-48">diltiazem | C22H26N2O4S - PubChem</source>. <ext-link l:rel="related" l:ref-type="uri" l:ref="https://pubchem.ncbi.nlm.nih.gov/compound/diltiazem" ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/diltiazem" hwp:id="ext-link-10">https://pubchem.ncbi.nlm.nih.gov/compound/diltiazem</ext-link>. <date-in-citation>Accessed 3 Feb 2017</date-in-citation>.</citation></ref><ref id="c50" hwp:id="ref-50" hwp:rev-id="xref-ref-50-1"><label>50.</label><citation publication-type="journal" citation-type="journal" ref:id="401315v1.50" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-50"><string-name name-style="western" hwp:sortable="Fujioka Y"><surname>Fujioka</surname> <given-names>Y</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nishide S"><surname>Nishide</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ose T"><surname>Ose</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Suzuki T"><surname>Suzuki</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kato I"><surname>Kato</surname> <given-names>I</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fukuhara H"><surname>Fukuhara</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-47">A Sialylated Voltage-Dependent Ca2+ Channel Binds Hemagglutinin and Mediates Influenza A Virus Entry into Mammalian Cells</article-title>. <source hwp:id="source-49">Cell Host Microbe</source>. <year>2018</year>;<volume>23</volume>:<fpage>809</fpage>–<lpage>818.e5</lpage>.</citation></ref></ref-list><sec sec-type="supplementary-material" id="s7" hwp:id="sec-37"><title hwp:id="title-48">Supplementary Materials</title><fig id="figS1" position="float" fig-type="figure" orientation="portrait" hwp:id="F7" hwp:rev-id="xref-fig-7-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/FIGS1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F7</object-id><object-id pub-id-type="publisher-id">figS1</object-id><label>Fig. S1.</label><caption hwp:id="caption-8"><title hwp:id="title-49">Decision tree used to rationally reduce the number of drug candidates.</title><p hwp:id="p-61">Bioactive molecules were excluded if not compatible with a final use as antiviral, mostly for safety (e.g. teratogens, intercalating agents) and/or pharmacological (e.g. documented low bioavailability) reasons. An additional selection level based on analysis of documented pharmacological actions was included, to finally define a shortlist of 35 representative molecules (&lt;3% of CMAP) for in vitro screening (<xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-5" hwp:rel-id="T1">Table 1</xref>).</p></caption><graphic xlink:href="401315_figS1" position="float" orientation="portrait" hwp:id="graphic-8"/></fig><fig id="figS2" position="float" fig-type="figure" orientation="portrait" hwp:id="F8" hwp:rev-id="xref-fig-8-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/FIGS2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F8</object-id><object-id pub-id-type="publisher-id">figS2</object-id><label>Fig. S2.</label><caption hwp:id="caption-9"><title hwp:id="title-50">Dose-response curves for the 35 molecules tested <italic toggle="yes">in vitro</italic>.</title><p hwp:id="p-62">In comparison with a mock-treated control, the impact of pre-treatment/treatment on % relative viral production (black line, left Y axis) and % relative cell viability (grey line, right Y axis) was measured at the indicated concentrations.</p></caption><graphic xlink:href="401315_figS2" position="float" orientation="portrait" hwp:id="graphic-9"/></fig><fig id="figS3" position="float" fig-type="figure" orientation="portrait" hwp:id="F9" hwp:rev-id="xref-fig-9-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/FIGS3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F9</object-id><object-id pub-id-type="publisher-id">figS3</object-id><label>Fig. S3.</label><caption hwp:id="caption-10"><title hwp:id="title-51">Efficacy and toxicity after oral administration of selected molecules in mice.</title><p hwp:id="p-63">(A) Survival curves of C57BL/6N mice (n=15/group), intranasally inoculated with 5 x 10<sup>5</sup> PFU of influenza A/Quebec/144147/09 virus on day 0 and treated by gavage with saline (grey), oseltamivir 10 mg/kg/day (red), lanatoside C 100 mg/kg/day (olive), prednisolone 5 mg/kg/day (dark blue), flucytosine 240 mg/kg/day (light blue), felbinac 5 mg/kg/day (fuchsia) or timolol 50 mg/kg/day (purple). A mock-infected, saline-treated group (black dotted line, n=6) was included as control. Treatments were initiated on day 0 (6 h before infection) and administered once daily for 5 consecutive days. (B) Body weight changes of mock-infected C57BL/6N mice (n=10/group) treated by gavage with saline (grey), oseltamivir 10 mg/kg/day (red), monensin 10 mg/kg/day (blue), diltiazem 90 mg/kg/day (green), or etilefrine 3 mg/kg/day (orange). A saline-treated group (black dotted line, n=6) was included as control. Treatments were initiated on day 0 (6 h before mock-infection) and administered once daily for 5 consecutive days.</p></caption><graphic xlink:href="401315_figS3" position="float" orientation="portrait" hwp:id="graphic-10"/></fig><fig id="figS4" position="float" fig-type="figure" orientation="portrait" hwp:id="F10"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/FIGS4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F10</object-id><object-id pub-id-type="publisher-id">figS4</object-id><label>Fig. S4.</label><caption hwp:id="caption-11"><title hwp:id="title-52">Diltiazem treatment effectively induces significant reversion of the viral infection signature.</title><p hwp:id="p-64">Stacked barplots with mean-weighted fold changes for the complete list of the 118 common differentially expressed transcripts (absolute fold change &gt;2, Benjamini-Hochberg corrected p-value &lt;0.05) between the mock + diltiazem (yellow), H1N1 (blue), and H1N1 + diltiazem (green) conditions. Barplots were constructed in R3.3.1 based on mean-weighted fold changes and ordered according to H1N1 values (blue).</p></caption><graphic xlink:href="401315_figS4" position="float" orientation="portrait" hwp:id="graphic-11"/></fig><table-wrap id="tblS1" orientation="portrait" position="float" hwp:id="T2"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/TBLS1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T2</object-id><object-id pub-id-type="publisher-id">tblS1</object-id><label>Table S1.</label><caption hwp:id="caption-12"><title hwp:id="title-53">Demographic and clinical characteristics of patients included in the study.</title><p hwp:id="p-65">Samples were obtained in the context of a previous clinical trial conducted in France during the A(H1N1)pdm09 pandemic, aimed at evaluating the antiviral efficacy and tolerability of classic antiviral monotherapy versus bitherapy (Escuret et al., 2012).</p></caption><graphic xlink:href="401315_tblS1" position="float" orientation="portrait" hwp:id="graphic-12"/></table-wrap><table-wrap id="tblS2" orientation="portrait" position="float" hwp:id="T3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/TBLS2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T3</object-id><object-id pub-id-type="publisher-id">tblS2</object-id><label>Table S2.</label><caption hwp:id="caption-13"><p hwp:id="p-66"><bold>List of 160 selected molecules and their documented pharmacological classes.</bold> The 35 selected compounds for <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> evaluation are highlighted in grey. Asterisks (*) indicate molecules previously evaluated for their antiviral properties against influenza viruses or other viruses according to the literature, and question marks (?) indicate absence of assigned pharmacological class. Documented pharmacological classes were obtained from PubChem (<ext-link l:rel="related" l:ref-type="uri" l:ref="https://pubchem.ncbi.nlm.nih.gov" ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov" hwp:id="ext-link-11">https://pubchem.ncbi.nlm.nih.gov</ext-link>).</p></caption><graphic xlink:href="401315_tblS2A" position="float" orientation="portrait" hwp:id="graphic-13"/><graphic xlink:href="401315_tblS2B" position="float" orientation="portrait" hwp:id="graphic-14"/><graphic xlink:href="401315_tblS2C" position="float" orientation="portrait" hwp:id="graphic-15"/><graphic xlink:href="401315_tblS2D" position="float" orientation="portrait" hwp:id="graphic-16"/></table-wrap><table-wrap id="tblS3" orientation="portrait" position="float" hwp:id="T4" hwp:rev-id="xref-table-wrap-4-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/TBLS3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T4</object-id><object-id pub-id-type="publisher-id">tblS3</object-id><label>Table S3.</label><caption hwp:id="caption-14"><p hwp:id="p-67"><bold>List of 35 selected molecules.</bold> CMAP concentration (µM) and calculated EC50 in the context of pre-treatment/treatment <italic toggle="yes">in vitro</italic>.</p></caption><graphic xlink:href="401315_tblS3" position="float" orientation="portrait" hwp:id="graphic-17"/></table-wrap><table-wrap id="tblS4" orientation="portrait" position="float" hwp:id="T5"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/TBLS4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T5</object-id><object-id pub-id-type="publisher-id">tblS4</object-id><label>Table S4.</label><caption hwp:id="caption-15"><p hwp:id="p-68"><bold>Evaluation of antiviral efficacy of diltiazem or etilefrine in the context of infection by different influenza strains.</bold> Human lung epithelial cells (A549) were incubated with supplemented medium (mock), or different concentrations of diltiazem (CMAP, 9 µM) or etilefrine (CMAP, 18 µM). Six hours after treatment, cells were washed and then infected with different prototype human influenza strains (as indicated). One hour after viral infection, a second identical treatment dose in supplemented medium was added. Relative viral titers compared to the mock-treated control are shown. Results are representative of two independent experiments, and confirm the antiviral activity of diltiazem and etilefrine on oseltamivir-resistant A(H1N1)pdm09, as well as wild-type H3N2 and B influenza strains.</p></caption><graphic xlink:href="401315_tblS4" position="float" orientation="portrait" hwp:id="graphic-18"/></table-wrap><table-wrap id="tblS5" orientation="portrait" position="float" hwp:id="T6"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/TBLS5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T6</object-id><object-id pub-id-type="publisher-id">tblS5</object-id><label>Table S5.</label><caption hwp:id="caption-16"><p hwp:id="p-69"><bold>Virus pre-incubation with diltiazem or etilefrine does not interfere with early viral entry steps.</bold> Two viral dilutions (#1 and #2, respectively 10<sup>6</sup> and 10<sup>5</sup> TCID50/mL) were pre-incubated for 1 h with PBS, diltiazem (CMAP, 9 µM), etilefrine (CMAP, 18 µM), or oseltamivir (1 µM). A(H1N1)pdm09 positive and a negative sera were used as controls. After incubation, viral titers (log10 TCID50/mL) were determined in MDCK cells. Results are representative of two independent experiments and indicate that pre-incubation with either diltiazem or etilefrine does not affect viral titers compared to PBS-incubated control, suggesting that the antiviral effect of these molecules is not mediated by direct drug-virus interactions at early stages of viral entry.</p></caption><graphic xlink:href="401315_tblS5" position="float" orientation="portrait" hwp:id="graphic-19"/></table-wrap><table-wrap id="tblS6" orientation="portrait" position="float" hwp:id="T7"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;401315v1/TBLS6</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T7</object-id><object-id pub-id-type="publisher-id">tblS6</object-id><label>Table S6.</label><caption hwp:id="caption-17"><title hwp:id="title-54">Apical viral production and transepithelial electrical resistance (TEER) in infected MucilAir<sup>®</sup> human airway epithelium (HAE).</title><p hwp:id="p-70">MucilAir<sup>®</sup> HAE were infected on the apical pole with influenza A/Lyon/969/09 (H1N1)pdm09 virus at a MOI of 0.1 and treated on the basolateral pole. Treatments were initiated 5 h after infection and were continued once daily for 4 additional days. *p&lt;0.05, **p&lt;0.01 and ***p&lt;0.001 compared to the infected mock-treated group by one-way ANOVA with Tukey’s post-test. Data are representative of at least three independent experiments.</p></caption><graphic xlink:href="401315_tblS6" position="float" orientation="portrait" hwp:id="graphic-20"/></table-wrap></sec></back></article>
